

# **Prop 65: What Happens in California Isn't Staying in California**

Alexandra L. Lizano  
Associate, Downey Brand

Emily Goswami  
Technical Director, Roux

## **Table of Contents**

<b>Label-Free: Court Concludes No Warning Label for Glyphosate – Brigit Rollins</b>	<b>Page 2</b>
<b>Safe Drinking Water and Toxic Enforcement Act of 1986 (a.k.a. Prop 65)</b>	<b>Page 5</b>
<b>Proposition 65 List</b>	<b>Page 14</b>

## Label-Free: Court Concludes No Warning Label for Glyphosate

A federal judge in the Eastern District of California has upheld the court's earlier decision that the state of California cannot require that cancer warning labels be placed on glyphosate-based products under California's Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as Proposition 65. The opinion, *Nat'l Ass'n of Wheat Growers v. Becerra*, No. 2:17-cv-02401 (E.D. Cal.), was issued June 22, 2020 and concludes that it would be a violation of the First Amendment of the United States Constitution to do so.

### Proposition 65

The California state law known as Proposition 65 requires the Governor of California to publish a list of chemicals known to the state to cause cancer. The California Office of Environmental Health Hazard Assessment ("OEHHA") is the state agency with authority to administer Proposition 65 and maintains the list of known carcinogens. As part of that list, OEHHA is required to include any chemical identified by the International Agency for Research on Cancer ("IARC") identifies as a carcinogen.

Proposition 65 also requires any person in the course of doing business to provide a "clear and reasonable" warning if they knowingly expose another person to one of the chemicals listed as a known carcinogen. Although the text of the statute does not specify what qualifies as a "clear and reasonable" warning, it gives two examples of "safe harbor" warnings which will satisfy the warning requirements of Proposition 65 when placed on products that contain chemicals listed under the statute. Both of these warnings are broad and state that the products on which they are placed are known to cause cancer.

### Background

In 2015, [IARC issued a report](#) which identified glyphosate as a "probable human carcinogen." As a result, glyphosate was listed under Proposition 65 and any product containing glyphosate was required to bear a warning label stating that the product was known to cause cancer. Glyphosate is one of the widest used pesticides in the United States. It is the primary ingredient of Roundup, a pesticide developed by Monsanto Company ("Monsanto"), now owned by Bayer. Roundup is registered under the Federal Insecticide, Fungicide, and Rodenticide Act and approved for use on over 100 food crops.

This case was originally filed in 2017 by a coalition of agriculture groups including Monsanto. In the original complaint, the plaintiffs argued that requiring Proposition 65 warning labels to be placed on all products containing glyphosate would violate the United States Constitution. First, the plaintiffs claimed that requiring warning labels to be put on any products containing glyphosate would violate the Free Speech Clause of the First Amendment by compelling speech that is "false and misleading." Second, the plaintiffs alleged that OEHHA has violated Article VI, Clause 2 of the United States Constitution, commonly known as the Supremacy Clause, which provides that state laws that conflict with federal law

are preempted and have no legal effect. The plaintiffs asked the court to issue an injunction, a court order that would prevent required labeling for pesticide products.

In 2018, the court issued such an order. The 2018 order was a preliminary injunction, meaning that the order was issued to maintain the status quo of the issues being litigated. To get a preliminary injunction, a party must show that it will suffer irreparable harm unless the injunction is issued. When making that determination, a court will consider whether the plaintiff is likely to succeed on the merits, whether the plaintiff is likely to suffer irreparable harm without the injunction, whether the balance of equities and hardships is in the plaintiff's favor, and whether an injunction is in the public interest. In this case, the court felt irreparable harm would take place if manufacturers were required to put Proposition 65 warning labels on glyphosate products before the case was fully resolved.

In its June 22 order, the court has granted a permanent injunction, meaning that the underlying issues have been resolved and glyphosate products will not require Proposition 65 labels going forward.

### **Court Opinion**

In its opinion, the court concluded that requiring glyphosate products to bear Proposition 65 labels was a violation of the First Amendment of the United States Constitution. Although Proposition 65 itself does not violate the First Amendment, the court found that it was unconstitutional as applied to glyphosate.

In reaching this conclusion, the court first noted that the label required by Proposition 65 was "compelled commercial speech." This means that the labels are speech that is legally required within the realm of commerce. In this case, Proposition 65 would have required any business to provide warnings if they knowingly exposed another person to glyphosate. In the vast majority of cases, the First Amendment prevents the government from either preventing or requiring a private party to make speech. However, the government *can* compel speech in certain circumstances, such as to protect public health and safety. Proposition 65 labels fall into the category of compelled commercial speech that is typically permitted because it protects public health and safety.

When reviewing challenges to Proposition 65 labels, the government has the burden of showing that the commercial speech it was compelling was "purely factual and uncontroversial." If the government cannot show do so, it must show that the speech is "neither misleading nor connected to unlawful activity." If the government cannot prove either of those things, then requiring the speech will violate the First Amendment, and may not be compelled.

Here, the court concluded that the Proposition 65 warning labels claiming that glyphosate was a known carcinogen failed both tests. According to the court, it was not factual to state that glyphosate was known to cause cancer when only IARC had identified glyphosate as a "probable human carcinogen." The court noted that other entities, including the Environmental Protection Agency and the World Health Organization, have concluded that glyphosate does not cause cancer or that there is not enough data to conclude that glyphosate is carcinogenic. Therefore, it would not be "factual" to state that glyphosate is known to cause cancer, failing the first of the government's tests. The court used the same reasoning to conclude that the government did not meet the second test, and it would be "misleading" to state that glyphosate is known to cause cancer.

Because the government did not meet either test, the court determined that it would be a violation of the First Amendment to require Proposition 65 labels be placed on products containing glyphosate.

## **Going Forward**

Following this decision, glyphosate is not subject to the warning requirements of Proposition 65. This means that anyone doing business in the state of California knowing that they will be exposing others to glyphosate, will not have to provide a warning. That includes a variety of people, ranging from retailers selling Roundup, groundskeeping businesses and those who employ them, and growers selling produce that has been exposed to glyphosate.

At this time, it is unknown whether the defendants will appeal this case. They have 30 days from the date that the judgement is filed in this case to appeal the court's decision. If they do appeal, they will do so to the Ninth Circuit.

This case does not affect any other litigation involving glyphosate, or any settlement that may be reached in other glyphosate cases.

## **HEALTH AND SAFETY CODE - HSC**

### **DIVISION 20. MISCELLANEOUS HEALTH AND SAFETY PROVISIONS [24000 - 26275]**

*( Division 20 enacted by Stats. 1939, Ch. 60. )*

#### **CHAPTER 6.6. Safe Drinking Water and Toxic Enforcement Act of 1986 [25249.5 - 25249.14]**

*( Chapter 6.6 added November 4, 1986, by initiative Proposition 65, Sec. 2. )*

**25249.5.** Prohibition On Contaminating Drinking Water With Chemicals Known to Cause Cancer or Reproductive Toxicity. No person in the course of doing business shall knowingly discharge or release a chemical known to the state to cause cancer or reproductive toxicity into water or onto or into land where such chemical passes or probably will pass into any source of drinking water, notwithstanding any other provision or authorization of law except as provided in Section 25249.9.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987.)*

**25249.6.** Required Warning Before Exposure To Chemicals Known to Cause Cancer Or Reproductive Toxicity. No person in the course of doing business shall knowingly and intentionally expose any individual to a chemical known to the state to cause cancer or reproductive toxicity without first giving clear and reasonable warning to such individual, except as provided in Section 25249.10.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987.)*

**25249.7.** (a) A person who violates or threatens to violate Section 25249.5 or 25249.6 may be enjoined in any court of competent jurisdiction.

(b) (1) A person who has violated Section 25249.5 or 25249.6 is liable for a civil penalty not to exceed two thousand five hundred dollars (\$2,500) per day for each violation in addition to any other penalty established by law. That civil penalty may be assessed and recovered in a civil action brought in any court of competent jurisdiction.

(2) In assessing the amount of a civil penalty for a violation of this chapter, the court shall consider all of the following:

(A) The nature and extent of the violation.

(B) The number of, and severity of, the violations.

(C) The economic effect of the penalty on the violator.

(D) Whether the violator took good faith measures to comply with this chapter and the time these measures were taken.

(E) The willfulness of the violator's misconduct.

(F) The deterrent effect that the imposition of the penalty would have on both the violator and the regulated community as a whole.

(G) Any other factor that justice may require.

(c) Actions pursuant to this section may be brought by the Attorney General in the name of the people of the State of California, by a district attorney, by a city attorney of a city having a population in excess of 750,000, or, with the consent of the district attorney, by a city prosecutor in a city or city and county having a full-time city prosecutor, or as provided in subdivision (d).

(d) Actions pursuant to this section may be brought by a person in the public interest if both of the following requirements are met:

(1) The private action is commenced more than 60 days from the date that the person has given notice of an alleged violation of Section 25249.5 or 25249.6 that is the subject of the private action to the Attorney General and the district attorney, city attorney, or prosecutor in whose jurisdiction the violation is alleged to have occurred, and to the alleged violator. If the notice alleges a violation of Section 25249.6, the notice of the alleged violation shall include a certificate of merit executed by the attorney for the noticing party, or by the noticing party, if the noticing party is not represented by an attorney. The certificate of merit shall state that the person executing the certificate has consulted with one or more persons with relevant and appropriate experience or expertise who has reviewed facts, studies, or other data regarding the exposure to the listed chemical that is the subject of the action, and that, based on that information, the person executing the certificate believes there is a reasonable and meritorious case for the private action. Factual information sufficient to establish the basis of the certificate of merit, including the information identified in paragraph (2) of subdivision (h), shall be attached to the certificate of merit that is served on the Attorney General.

(2) Neither the Attorney General, a district attorney, a city attorney, nor a prosecutor has commenced and is diligently prosecuting an action against the violation.

(e) (1) (A) If, after reviewing the factual information sufficient to establish the basis for the certificate of merit and meeting and conferring with the noticing party regarding the basis for the certificate of merit, the Attorney General believes there is no merit to the action, the Attorney General shall serve a letter to the noticing party and the alleged violator stating the Attorney General believes there is no merit to the action.

(B) If the Attorney General does not serve a letter pursuant to subparagraph (A), this shall not be construed as an endorsement by the Attorney General of the merit of the action.

(2) A person bringing an action in the public interest pursuant to subdivision (d) and a person filing an action in which a violation of this chapter is alleged shall notify the Attorney General that the action has been filed. Neither this subdivision nor the procedures provided in subdivisions (f) to (k), inclusive, affect the requirements imposed by statute or a court decision

in existence on January 1, 2002, concerning whether a person filing an action in which a violation of this chapter is alleged is required to comply with the requirements of subdivision (d).

(f) (1) A person filing an action in the public interest pursuant to subdivision (d), a private person filing an action in which a violation of this chapter is alleged, or a private person settling a violation of this chapter alleged in a notice given pursuant to paragraph (1) of subdivision (d), shall, after the action or violation is subject either to a settlement or to a judgment, submit to the Attorney General a reporting form that includes the results of that settlement or judgment and the final disposition of the case, even if dismissed. At the time of the filing of a judgment pursuant to an action brought in the public interest pursuant to subdivision (d), or an action brought by a private person in which a violation of this chapter is alleged, the plaintiff shall file an affidavit verifying that the report required by this subdivision has been accurately completed and submitted to the Attorney General.

(2) A person bringing an action in the public interest pursuant to subdivision (d), or a private person bringing an action in which a violation of this chapter is alleged, shall, after the action is either subject to a settlement, with or without court approval, or to a judgment, submit to the Attorney General a report that includes information on any corrective action being taken as a part of the settlement or resolution of the action.

(3) The Attorney General shall develop a reporting form that specifies the information that shall be reported, including, but not limited to, for purposes of paragraph (2) of subdivision (e), the date the action was filed, the nature of the relief sought, and for purposes of this subdivision, the amount of the settlement or civil penalty assessed, other financial terms of the settlement, and any other information the Attorney General deems appropriate.

(4) If there is a settlement of an action brought by a person in the public interest under subdivision (d), the plaintiff shall submit the settlement, other than a voluntary dismissal in which no consideration is received from the defendant, to the court for approval upon noticed motion, and the court may approve the settlement only if the court makes all of the following findings:

(A) The warning that is required by the settlement complies with this chapter.

(B) The award of attorney's fees is reasonable under California law.

(C) The penalty amount is reasonable based on the criteria set forth in paragraph (2) of subdivision (b).

(5) The plaintiff subject to paragraph (4) has the burden of producing evidence sufficient to sustain each required finding. The plaintiff shall serve the motion and all supporting papers on the Attorney General, who may appear and participate in a proceeding without intervening in the case.

(6) Neither this subdivision nor the procedures provided in paragraph (2) of subdivision (e) and subdivisions (g) to (k), inclusive, affect the requirements imposed by statute or a court decision in existence on January 1, 2002, concerning whether claims raised by a person or public prosecutor not a party to the action are precluded by a settlement approved by the court.

(g) The Attorney General shall maintain a record of the information submitted pursuant to subdivisions (e) and (f) and shall make this information available to the public.

(h) (1) The basis for the certificate of merit required by subdivision (d) is discoverable only to the extent that the information is relevant to the subject matter of the action and not subject to the attorney-client privilege, the attorney work product privilege, or any other legal privilege.

(2) Upon the conclusion of an action brought pursuant to subdivision (d) with respect to a defendant, if the trial court determines that there was no actual or threatened exposure to a listed chemical, the court may, upon the motion of that alleged violator or upon the court's own motion, review the basis for the belief of the person executing the certificate of merit, expressed in the certificate of merit, that an exposure to a listed chemical had occurred or was threatened. The information in the certificate of merit, including the identity of the persons consulted with and relied on by the certifier, and the facts, studies, or other data reviewed by those persons, shall be disclosed to the court in an in-camera proceeding at which the moving party shall not be present. If the court finds that there was no credible factual basis for the certifier's belief that an exposure to a listed chemical had occurred or was threatened, then the action shall be deemed frivolous within the meaning of Section 128.5 of the Code of Civil Procedure. The court shall not find a factual basis credible on the basis of a legal theory of liability that is frivolous within the meaning of Section 128.5 of the Code of Civil Procedure.

(i) The Attorney General may provide the factual information submitted to establish the basis of the certificate of merit on request to a district attorney, city attorney, or prosecutor within whose jurisdiction the violation is alleged to have occurred, or to any other state or federal government agency, but in all other respects the Attorney General shall maintain, and ensure that all recipients maintain, the submitted information as confidential official information to the full extent authorized in Section 1040 of the Evidence Code.

(j) In an action brought by the Attorney General, a district attorney, a city attorney, or a prosecutor pursuant to this chapter, the Attorney General, district attorney, city attorney, or prosecutor may seek and recover costs and attorney's fees on behalf of a party who provides a notice pursuant to subdivision (d) and who renders assistance in that action.

(k) Any person who serves a notice of alleged violation pursuant to paragraph (1) of subdivision (d) for an exposure identified in subparagraph (A), (B), (C), or (D) of paragraph (1) shall complete, as appropriate, and provide to the alleged violator at the time the notice of alleged violation is served, a notice of special compliance procedure and proof of compliance form pursuant to subdivision (l) and shall not file an action for that exposure against the alleged violator, or recover from the alleged violator in a settlement any payment in lieu of penalties or any reimbursement for costs and attorney's fees, if all of the following conditions have been met:

(1) The notice given pursuant to paragraph (1) of subdivision (d) was served on or after the effective date of the act amending this section during the 2013–14 Regular Session and alleges that the alleged violator failed to provide clear and reasonable warning as required under Section 25249.6 regarding one or more of the following:

(A) An exposure to alcoholic beverages that are consumed on the alleged violator's premises to the extent onsite consumption is permitted by law.

(B) An exposure to a chemical known to the state to cause cancer or reproductive toxicity in a food or beverage prepared and sold on the alleged violator's premises primarily



intended for immediate consumption on or off premises, to the extent of both of the following:

(i) The chemical was not intentionally added.

(ii) The chemical was formed by cooking or similar preparation of food or beverage components necessary to render the food or beverage palatable or to avoid microbiological contamination.

(C) An exposure to environmental tobacco smoke caused by entry of persons (other than employees) on premises owned or operated by the alleged violator where smoking is permitted at any location on the premises.

(D) An exposure to chemicals known to the state to cause cancer or reproductive toxicity in engine exhaust, to the extent the exposure occurs inside a facility owned or operated by the alleged violator and primarily intended for parking noncommercial vehicles.

(2) Within 14 days after service of the notice, the alleged violator has done all of the following:

(A) Corrected the alleged violation.

(B) (i) Agreed to pay a civil penalty for the alleged violation of Section 25249.6 in the amount of five hundred dollars (\$500), to be adjusted quinquennially pursuant to clause (ii), per facility or premises where the alleged violation occurred, of which 75 percent shall be deposited in the Safe Drinking Water and Toxic Enforcement Fund, and 25 percent shall be paid to the person that served the notice as provided in Section 25249.12.

(ii) On April 1, 2019, and at each five-year interval thereafter, the dollar amount of the civil penalty provided pursuant to this subparagraph shall be adjusted by the Judicial Council based on the change in the annual California Consumer Price Index for All Urban Consumers, published by the Department of Industrial Relations, Division of Labor Statistics and Research, for the most recent five-year period ending on December 31 of the year preceding the year in which the adjustment is made, rounded to the nearest five dollars (\$5). The Judicial Council shall quinquennially publish the dollar amount of the adjusted civil penalty provided pursuant to this subparagraph, together with the date of the next scheduled adjustment.

(C) Notified, in writing, the person that served the notice of the alleged violation, that the violation has been corrected. The written notice shall include the notice of special compliance procedure and proof of compliance form specified in subdivision (1), which was provided by the person serving notice of the alleged violation and which shall be completed by the alleged violator as directed in the notice.

(3) The alleged violator shall deliver the civil penalty to the person that served the notice of the alleged violation within 30 days of service of that notice, and the person that served the notice of violation shall remit the portion of the penalty due to the Safe Drinking Water and Toxic Enforcement Fund within 30 days of receipt of the funds from the alleged violator.

(l) The notice required to be provided to an alleged violator pursuant to subdivision (k) shall be presented as follows:

\*\*\*\*\*

NOTICE OF INCOMPLETE TEXT: The Proof of Compliance form appears in the published bill. See Sec. 1, Chapter 187 (pp. 7–8), Statutes of 2019.

\*\*\*\*\*

(m) An alleged violator may satisfy the conditions set forth in subdivision (k) only one time for a violation arising from the same exposure in the same facility or on the same premises.

(n) Nothing in subdivision (k) shall prevent the Attorney General, a district attorney, a city attorney, or a prosecutor in whose jurisdiction the violation is alleged to have occurred from filing an action pursuant to subdivision (c) against an alleged violator. In any such action, the amount of any civil penalty for a violation shall be reduced to reflect any payment made by the alleged violator for the same alleged violation pursuant to subparagraph (B) of paragraph (2) of subdivision (k).

(o) If a violation of this chapter is alleged or the application or construction of provisions of this chapter is at issue in a proceeding in the Supreme Court, court of appeal, or the appellate division of the superior court, each party shall serve a copy of the party’s brief or petition and brief, on the Attorney General. Service on the Attorney General shall be accomplished by serving the brief, or petition and brief, on the Proposition 65 coordinator at the service address designated on the Attorney General’s internet website for Proposition 65 enforcement reporting. A brief shall not be accepted or filed unless the proof of service shows service on the Attorney General. A party failing to comply with this subdivision shall be given a reasonable opportunity to cure the failure before the court imposes sanction, and, in that instance, the court shall allow the Attorney General reasonable additional time to file a brief in the matter.

*(Amended by Stats. 2019, Ch. 187, Sec. 1. (AB 1123) Effective January 1, 2020. Note: See published chaptered bill for complete section text. The Proof of Compliance form appears on pages 7 to 8 of Stats. 2019, Ch. 187. Note: This section was added on Nov. 4, 1986, by initiative Prop. 65.)*

**25249.8.** List Of Chemicals Known to Cause Cancer Or Reproductive Toxicity.

(a) On or before March 1, 1987, the Governor shall cause to be published a list of those chemicals known to the state to cause cancer or reproductive toxicity within the meaning of this chapter, and he shall cause such list to be revised and republished in light of additional knowledge at least once per year thereafter. Such list shall include at a minimum those substances identified by reference in Labor Code Section 6382(b)(1) and those substances identified additionally by reference in Labor Code Section 6382(d).

(b) A chemical is known to the state to cause cancer or reproductive toxicity within the meaning of this chapter if in the opinion of the state’s qualified experts it has been clearly shown through scientifically valid testing according to generally accepted principles to cause cancer or reproductive toxicity, or if a body considered to be authoritative by such experts has formally identified it as causing cancer or reproductive toxicity, or if an agency of the state or federal government has formally required it to be labeled or identified as causing cancer or reproductive toxicity.

(c) On or before January 1, 1989, and at least once per year thereafter, the Governor shall cause to be published a separate list of those chemicals that at the time of publication are required by state or federal law to have been tested for potential to cause cancer or reproductive toxicity but that the state's qualified experts have not found to have been adequately tested as required.

(d) The Governor shall identify and consult with the state's qualified experts as necessary to carry out his duties under this section.

(e) In carrying out the duties of the Governor under this section, the Governor and his designates shall not be considered to be adopting or amending a regulation within the meaning of the Administrative Procedure Act as defined in Government Code Section 11370.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987.)*

**25249.9.** Exemptions from Discharge Prohibition.

(a) Section 25249.5 shall not apply to any discharge or release that takes place less than twenty months subsequent to the listing of the chemical in question on the list required to be published under subdivision (a) of Section 25249.8.

(b) Section 25249.5 shall not apply to any discharge or release that meets both of the following criteria:

(1) The discharge or release will not cause any significant amount of the discharged or released chemical to enter any source of drinking water.

(2) The discharge or release is in conformity with all other laws and with every applicable regulation, permit, requirement, and order.

In any action brought to enforce Section 25249.5, the burden of showing that a discharge or release meets the criteria of this subdivision shall be on the defendant.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987.)*

**25249.10.** Exemptions from Warning Requirement.

Section 25249.6 shall not apply to any of the following:

(a) An exposure for which federal law governs warning in a manner that preempts state authority.

(b) An exposure that takes place less than twelve months subsequent to the listing of the chemical in question on the list required to be published under subdivision (a) of Section 25249.8.

(c) An exposure for which the person responsible can show that the exposure poses no significant risk assuming lifetime exposure at the level in question for substances known to the state to cause cancer, and that the exposure will have no observable effect assuming exposure at one thousand (1000) times the level in question for substances known to the state to cause reproductive toxicity, based on evidence and standards of comparable scientific validity to the evidence and standards which form the scientific basis for the listing of such chemical pursuant to subdivision (a) of Section 25249.8. In any action brought to enforce Section 25249.6, the burden of showing that an exposure meets the criteria of this subdivision shall be on the defendant.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987.)*

**25249.11.** Definitions.

For purposes of this chapter:

- (a) "Person" means an individual, trust, firm, joint stock company, corporation, company, partnership, limited liability company, and association.
- (b) "Person in the course of doing business" does not include any person employing fewer than 10 employees in his or her business; any city, county, or district or any department or agency thereof or the state or any department or agency thereof or the federal government or any department or agency thereof; or any entity in its operation of a public water system as defined in Section 116275.
- (c) "Significant amount" means any detectable amount except an amount which would meet the exemption test in subdivision (c) of Section 25249.10 if an individual were exposed to such an amount in drinking water.
- (d) "Source of drinking water" means either a present source of drinking water or water which is identified or designated in a water quality control plan adopted by a regional board as being suitable for domestic or municipal uses.
- (e) "Threaten to violate" means to create a condition in which there is a substantial probability that a violation will occur.
- (f) "Warning" within the meaning of Section 25249.6 need not be provided separately to each exposed individual and may be provided by general methods such as labels on consumer products, inclusion of notices in mailings to water customers, posting of notices, placing notices in public news media, and the like, provided that the warning accomplished is clear and reasonable. In order to minimize the burden on retail sellers of consumer products including foods, regulations implementing Section 25249.6 shall to the extent practicable place the obligation to provide any warning materials such as labels on the producer or packager rather than on the retail seller, except where the retail seller itself is responsible for introducing a chemical known to the state to cause cancer or reproductive toxicity into the consumer product in question.

*(Amended by Stats. 1996, Ch. 1023, Sec. 238. Effective September 29, 1996. Note: This section was added on Nov. 4, 1986, by initiative Prop. 65.)*

**25249.12.** (a) The Governor shall designate a lead agency and other agencies that may be required to implement this chapter, including this section. Each agency so designated may adopt and modify regulations, standards, and permits as necessary to conform with and implement this chapter and to further its purposes.

(b) The Safe Drinking Water and Toxic Enforcement Fund is hereby established in the State Treasury. The director of the lead agency designated by the Governor to implement this chapter may expend the funds in the Safe Drinking Water and Toxic Enforcement Fund, upon appropriation by the Legislature, to implement and administer this chapter.

(c) In addition to any other money that may be deposited in the Safe Drinking Water and Toxic Enforcement Fund, all of the following amounts shall be deposited in the fund:

(1) Seventy-five percent of all civil and criminal penalties collected pursuant to this chapter.

(2) Any interest earned upon the money deposited into the Safe Drinking Water and Toxic Enforcement Fund.

(d) Twenty-five percent of all civil and criminal penalties collected pursuant to this chapter shall be paid to the office of the city attorney, city prosecutor, district attorney, or Attorney General,

whichever office brought the action, or in the case of an action brought by a person under subdivision (d) of Section 25249.7, to that person.

*(Amended by Stats. 2003, Ch. 228, Sec. 22. Effective August 11, 2003. Note: This section was added on Nov. 4, 1986, by initiative Prop. 65.)*

**25249.13.** Preservation Of Existing Rights, Obligations, and Penalties. Nothing in this chapter shall alter or diminish any legal obligation otherwise required in common law or by statute or regulation, and nothing in this chapter shall create or enlarge any defense in any action to enforce such legal obligation. Penalties and sanctions imposed under this chapter shall be in addition to any penalties or sanctions otherwise prescribed by law.

*(Added November 4, 1986, by initiative Proposition 65. Operative January 1, 1987. Note: Sections 25250 to 25259 are in Articles 13 to 17 of Chapter 6.5, following Section 25249.2.)*

**25249.14.** The Governor's Office of Business and Economic Development shall post in a conspicuous location on its Internet Web site, and include with any informational materials provided to businesses relating to a business's obligations under state law, a disclaimer that states the following:

Proposition 65, officially known as the Safe Drinking Water and Toxic Enforcement Act of 1986, requires businesses to provide a clear and reasonable warning before knowingly and intentionally exposing anyone to chemicals that are known to the state to cause cancer or birth defects or other reproductive harm. It is important to know that a product that receives certification from the United States Food and Drug Administration, or another federal agency or state agency, is not necessarily exempt from California requirements for chemical exposure warnings. Businesses should be aware of the levels of harmful chemicals in their products and of applicable Proposition 65 requirements. For more information on Proposition 65 and how to comply with its requirements, please visit <https://oehha.ca.gov>.

*(Added by Stats. 2017, Ch. 510, Sec. 2. (AB 1583) Effective January 1, 2018.)*

STATE OF CALIFORNIA  
 ENVIRONMENTAL PROTECTION AGENCY  
 OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT  
 SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986

CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY  
 April 21, 2023

The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and republish at least once per year the list of chemicals known to the State to cause cancer or reproductive toxicity. The identification number indicated in the following list is the Chemical Abstracts Service (CAS) Registry Number. No CAS number is given when several substances are presented as a single listing. The date refers to the initial appearance of the chemical on the list. For easy reference, chemicals which are shown underlined are newly added. Chemicals or endpoints shown in ~~strikeout~~ were placed on the Proposition 65 list on the date noted, and have subsequently been removed.

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
A-alpha-C (2-Amino-9H-pyrido [2,3-b]indole)	Cancer	26148-68-5	January 1, 1990
Abiraterone acetate	developmental, female, male	154229-18-2	April 8, 2016
Acetaldehyde	cancer	75-07-0	April 1, 1988
Acetamide	cancer	60-35-5	January 1, 1990
Acetazolamide	developmental	59-66-5	August 20, 1999
Acetochlor	cancer	34256-82-1	January 1, 1989
Acetohydroxamic acid	developmental	546-88-3	April 1, 1990
2-Acetylaminofluorene	cancer	53-96-3	July 1, 1987
Acifluorfen sodium	cancer	62476-59-9	January 1, 1990
Acrylamide	cancer	79-06-1	January 1, 1990
Acrylamide	developmental, male	79-06-1	February 25, 2011
Acrylonitrile	cancer	107-13-1	July 1, 1987
Actinomycin D	cancer	50-76-0	October 1, 1989
Actinomycin D	developmental	50-76-0	October 1, 1992
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)] acrylamide	cancer	3688-53-7	July 1, 1987
Aflatoxins	cancer	---	January 1, 1988
Alachlor	cancer	15972-60-8	January 1, 1989
Alcoholic beverages	cancer	---	April 29, 2011
Alcoholic beverages, when associated with alcohol abuse	cancer	---	July 1, 1988
Aldrin	cancer	309-00-2	July 1, 1988
All-trans retinoic acid	developmental	302-79-4	January 1, 1989
<u>Allyl chloride, <del>Delisted October 29, 1999</del></u>	<u>cancer</u>	<u>107-05-1</u>	<u>January 1, 1990</u>
Aloe vera, non-decolorized whole leaf extract	cancer	---	December 4, 2015
Alprazolam	developmental	28981-97-7	July 1, 1990
Altretamine	developmental, male	645-05-6	August 20, 1999
Amantadine hydrochloride	developmental	665-66-7	February 27, 2001
Amikacin sulfate	developmental	39831-55-5	July 1, 1990
2-Aminoanthraquinone	cancer	117-79-3	October 1, 1989
p-Aminoazobenzene	cancer	60-09-3	January 1, 1990
o-Aminoazotoluene	cancer	97-56-3	July 1, 1987

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
4-Aminobiphenyl (4-amino-diphenyl)	cancer	92-67-1	February 27, 1987
2-Amino-4-chlorophenol	cancer	95-85-2	September 13, 2019
1-Amino-2,4-dibromo-anthraquinone	cancer	81-49-2	August 26, 1997
3-Amino-9-ethylcarbazole hydrochloride	cancer	6109-97-3	July 1, 1989
2-Aminofluorene	cancer	153-78-6	January 29, 1999
Aminoglutethimide	developmental	125-84-8	July 1, 1990
Aminoglycosides	developmental	---	October 1, 1992
1-Amino-2-methylantraquinone	cancer	82-28-0	October 1, 1989
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	cancer	712-68-5	July 1, 1987
4-Amino-2-nitrophenol	cancer	119-34-6	January 29, 1999
Aminopterin	developmental, female	54-62-6	July 1, 1987
Amiodarone hydrochloride	developmental, female, male	19774-82-4	August 26, 1997
Amitraz	developmental	33089-61-1	March 30, 1999
Amitrole	cancer	61-82-5	July 1, 1987
Amoxapine	developmental	14028-44-5	May 15, 1998
Amsacrine	cancer	51264-14-3	August 7, 2009
<a href="#">tert Amyl methyl ether, Delisted December 13, 2013</a>	<a href="#">developmental</a>	<a href="#">994-05-8</a>	<a href="#">December 18, 2009</a>
Anabolic steroids	female, male	---	April 1, 1990
Analgesic mixtures containing phenacetin	cancer	---	February 27, 1987
Androstenedione	cancer	63-05-8	May 3, 2011
Angiotensin converting enzyme (ACE) inhibitors	developmental	---	October 1, 1992
Aniline	cancer	62-53-3	January 1, 1990
Aniline hydrochloride	cancer	142-04-1	May 15, 1998
o-Anisidine	cancer	90-04-0	July 1, 1987
o-Anisidine hydrochloride	cancer	134-29-2	July 1, 1987
Anisindione	developmental	117-37-3	October 1, 1992
Anthraquinone	cancer	84-65-1	September 28, 2007
Antimony oxide (Antimony trioxide)	cancer	1309-64-4	October 1, 1990
Aramite	cancer	140-57-8	July 1, 1987
Areca nut	cancer	---	February 3, 2006
Aristolochic acids	cancer	---	July 9, 2004
Arsenic (inorganic arsenic compounds)	cancer	--	February 27, 1987
Arsenic (inorganic oxides)	developmental	---	May 1, 1997
Asbestos	cancer	1332-21-4	February 27, 1987
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	developmental, female	50-78-2	July 1, 1990
Atenolol	developmental	29122-68-7	August 26, 1997
Atrazine	developmental, female	1912-24-9	July 15, 2016
Auramine	cancer	492-80-8	July 1, 1987
Auranofin	developmental	34031-32-8	January 29, 1999
Avermectin B1 (Abamectin)	developmental	71751-41-2	December 3, 2010
Azacitidine	cancer	320-67-2	January 1, 1992
Azaserine	cancer	115-02-6	July 1, 1987

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Azathioprine	cancer	446-86-6	February 27, 1987
Azathioprine	developmental	446-86-6	September 1, 1996
Azobenzene	cancer	103-33-3	January 1, 1990
Barbiturates	developmental	---	October 1, 1992
Beclomethasone dipropionate	developmental	5534-09-8	May 15, 1998
Benomyl	developmental, male	17804-35-2	July 1, 1991
Benthiavalicarb-isopropyl	cancer	177406-68-7	July 1, 2008
Benz[a]anthracene	cancer	56-55-3	July 1, 1987
Benzene	cancer	71-43-2	February 27, 1987
Benzene	developmental, male	71-43-2	December 26, 1997
Benzidine [and its salts]	cancer	92-87-5	February 27, 1987
Benzidine-based dyes	cancer	---	October 1, 1992
Benzodiazepines	developmental	---	October 1, 1992
Benzo[b]fluoranthene	cancer	205-99-2	July 1, 1987
Benzo[j]fluoranthene	cancer	205-82-3	July 1, 1987
Benzo[k]fluoranthene	cancer	207-08-9	July 1, 1987
Benzofuran	cancer	271-89-6	October 1, 1990
Benzophenone	cancer	119-61-9	June 22, 2012
Benzo[a]pyrene	cancer	50-32-8	July 1, 1987
Benzotrichloride	cancer	98-07-7	July 1, 1987
Benzphetamine hydrochloride	developmental	5411-22-3	April 1, 1990
Benzyl chloride	cancer	100-44-7	January 1, 1990
Benzyl violet 4B	cancer	1694-09-3	July 1, 1987
Beryllium and beryllium compounds	cancer	---	October 1, 1987
Betel quid with tobacco	cancer	---	January 1, 1990
Betel quid without tobacco	cancer	---	February 3, 2006
Bevacizumab	developmental, female	216974-75-3	March 8, 2019
2,2-Bis(bromomethyl)-1,3-propanediol	cancer	3296-90-0	May 1, 1996
Bis(2-chloroethyl)ether	cancer	111-44-4	April 1, 1988
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	cancer	494-03-1	February 27, 1987
Bischloroethyl nitrosourea (BCNU) (Carmustine)	cancer	154-93-8	July 1, 1987
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	154-93-8	July 1, 1990
Bis(chloromethyl)ether	cancer	542-88-1	February 27, 1987
Bis(2-chloro-1-methylethyl)ether, technical grade	cancer	---	October 29, 1999
Bisphenol A (BPA)	female	80-05-7	May 11, 2015
Bisphenol A (BPA)	developmental	80-05-7	December 18, 2020
Bitumens, extracts of steam-refined and air refined	cancer	---	January 1, 1990
Bracken fern	cancer	---	January 1, 1990
Bromacil lithium salt	developmental	53404-19-6	May 18, 1999
Bromacil lithium salt	male	53404-19-6	January 17, 2003
Bromate	cancer	15541-45-4	May 31, 2002
Bromochloroacetic acid	cancer	5589-96-8	April 6, 2010
1-Bromo-3-chloropropane	cancer	109-70-6	January 27, 2023
Bromodichloroacetic acid	cancer	71133-14-7	July 29, 2016
Bromodichloromethane	cancer	75-27-4	January 1, 1990
Bromoethane	cancer	74-96-4	December 22, 2000
Bromoform	cancer	75-25-2	April 1, 1991
1-Bromopropane (1-BP)	cancer	106-94-5	August 5, 2016



<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
1-Bromopropane (1-BP)	developmental, female, male	106-94-5	December 7, 2004
2-Bromopropane (2-BP)	female, male	75-26-3	May 31, 2005
Bromoxynil	developmental	1689-84-5	October 1, 1990
Bromoxynil octanoate	developmental	1689-99-2	May 18, 1999
Butabarbital sodium	developmental	143-81-7	October 1, 1992
1,3-Butadiene	cancer	106-99-0	April 1, 1988
1,3-Butadiene	developmental, female, male	106-99-0	April 16, 2004
1,4-Butanediol dimethanesulfonate (Busulfan)	cancer	55-98-1	February 27, 1987
1,4-Butanediol dimethanesulfonate (Busulfan)	developmental	55-98-1	January 1, 1989
Butylated hydroxyanisole	cancer	25013-16-5	January 1, 1990
Butyl benzyl phthalate (BBP)	developmental	85-68-7	December 2, 2005
1-Butyl glycidyl ether	cancer	2426-08-6	January 27, 2023
<del>n-Butyl glycidyl ether, Delisted April 4, 2014</del>	<del>male</del>	<del>2426-08-6</del>	<del>August 7, 2009</del>
beta-Butyrolactone	cancer	3068-88-0	July 1, 1987
Cacodylic acid	cancer	75-60-5	May 1, 1996
Cadmium	developmental, male	---	May 1, 1997
Cadmium and cadmium compounds	cancer	---	October 1, 1987
Caffeic acid	cancer	331-39-5	October 1, 1994
Cannabis (marijuana) smoke	developmental	---	January 3, 2020
Captafol	cancer	2425-06-1	October 1, 1988
Captan	cancer	133-06-2	January 1, 1990
Carbamazepine	developmental	298-46-4	January 29, 1999
Carbaryl	cancer	63-25-2	February 5, 2010
Carbaryl	developmental, female, male	63-25-2	August 7, 2009
Carbazole	cancer	86-74-8	May 1, 1996
Carbon black (airborne, unbound particles of respirable size)	cancer	1333-86-4	February 21, 2003
Carbon-black extracts	cancer	---	January 1, 1990
Carbon disulfide	developmental, female, male	75-15-0	July 1, 1989
Carbon monoxide	developmental	630-08-0	July 1, 1989
Carbon tetrachloride	cancer	56-23-5	October 1, 1987
Carboplatin	developmental	41575-94-4	July 1, 1990
N-Carboxymethyl-N-nitrosourea	cancer	60391-92-6	January 25, 2002
Catechol	cancer	120-80-9	July 15, 2003
Ceramic fibers (airborne particles of respirable size)	cancer	---	July 1, 1990
Certain combined chemotherapy for lymphomas	cancer	---	February 27, 1987
Chenodiol	developmental	474-25-9	April 1, 1990
Chloral	cancer	75-87-6	September 13, 2013
Chloral hydrate	cancer	302-17-0	September 13, 2013
Chlorambucil	cancer	305-03-3	February 27, 1987
Chlorambucil	developmental	305-03-3	January 1, 1989
<del>Chloramphenicol, Delisted January 4, 2013</del>	<del>cancer</del>	<del>56-75-7</del>	<del>October 1, 1989</del>
Chloramphenicol sodium succinate	cancer	982-57-0	September 27, 2013
Chlorcyclizine hydrochloride	developmental	1620-21-9	July 1, 1987
Chlordane	cancer	57-74-9	July 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Chlordecone (Kepone)	cancer	143-50-0	January 1, 1988
Chlordecone (Kepone)	developmental	143-50-0	January 1, 1989
Chlordiazepoxide	developmental	58-25-3	January 1, 1992
Chlordiazepoxide hydrochloride	developmental	438-41-5	January 1, 1992
Chlordimeform	cancer	6164-98-3	January 1, 1989
Chlorendic acid	cancer	115-28-6	July 1, 1989
Chlorinated paraffins (Average chain length, C12; approximately 60 percent chlorine by weight)	cancer	108171-26-2	July 1, 1989
<i>p</i> -Chloroaniline	cancer	106-47-8	October 1, 1994
<i>p</i> -Chloroaniline hydrochloride	cancer	20265-96-7	May 15, 1998
<a href="#">Chlorodibromomethane, Delisted October 29, 1999</a>	<del>cancer</del>	<del>124-48-1</del>	<del>January 1, 1990</del>
Chloroethane (Ethyl chloride)	cancer	75-00-3	July 1, 1990
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	cancer	13010-47-4	January 1, 1988
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Lomustine)	developmental	13010-47-4	July 1, 1990
1-(2-Chloroethyl)-3-(4-methyl-cyclohexyl) -1-nitrosourea (Methyl-CCNU)	cancer	13909-09-6	October 1, 1988
Chloroform	cancer	67-66-3	October 1, 1987
Chloroform	developmental	67-66-3	August 7, 2009
Chloromethyl methyl ether (technical grade)	cancer	107-30-2	February 27, 1987
3-Chloro-2-methylpropene	cancer	563-47-3	July 1, 1989
1-Chloro-4-nitrobenzene	cancer	100-00-5	October 29, 1999
2-Chloronitrobenzene	cancer	88-73-3	September 13, 2019
4-Chloro- <i>o</i> -phenylenediamine	cancer	95-83-0	January 1, 1988
Chloroprene	cancer	126-99-8	June 2, 2000
2-Chloropropionic acid	male	598-78-7	August 7, 2009
Chlorothalonil	cancer	1897-45-6	January 1, 1989
<i>p</i> -Chloro- <i>o</i> -toluidine	cancer	95-69-2	January 1, 1990
<i>p</i> -Chloro- <i>o</i> -toluidine, strong acid salts of	cancer	---	May 15, 1998
5-Chloro- <i>o</i> -toluidine and its strong acid salts	cancer	---	October 24, 1997
Chlorotrianisene	cancer	569-57-3	September 1, 1996
<i>p</i> -chloro- $\alpha, \alpha, \alpha$ -trifluorotoluene ( <i>para</i> -Chlorobenzotrifluoride, PCBTF)	cancer	98-56-6	June 28, 2019
Chlorozotocin	cancer	54749-90-5	January 1, 1992
Chlorpyrifos	developmental	2921-88-2	December 15, 2017
<a href="#">Chlorsulfuron, Delisted June 6, 2014</a>	<del>developmental, female, male</del>	<del>64902-72-3</del>	<del>May 14, 1999</del>
Chromium (hexavalent compounds)	cancer	---	February 27, 1987
Chromium (hexavalent compounds)	developmental, female, male	---	December 19, 2008
Chrysene	cancer	218-01-9	January 1, 1990
C.I. Acid Red 114	cancer	6459-94-5	July 1, 1992
C.I. Basic Red 9 monohydrochloride	cancer	569-61-9	July 1, 1989
C.I. Direct Blue 15	cancer	2429-74-5	August 26, 1997
C.I. Direct Blue 218	cancer	28407-37-6	August 26, 1997
C.I. Disperse Yellow 3	cancer	2832-40-8	February 8, 2013
C.I. Solvent Yellow 14	cancer	842-07-9	May 15, 1998

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Ciclosporin (Cyclosporin A; Cyclosporine)	cancer	59865-13-3; 79217-60-0	January 1, 1992
Cidofovir	cancer, developmental, female, male	113852-37-2	January 29, 1999
Cinnamyl anthranilate	cancer	87-29-6	July 1, 1989
Cisplatin	cancer	15663-27-1	October 1, 1988
Citrus Red No. 2	cancer	6358-53-8	October 1, 1989
Cladribine	developmental	4291-63-8	September 1, 1996
Clarithromycin	developmental	81103-11-9	May 1, 1997
Clobetasol propionate	developmental, female	25122-46-7	May 15, 1998
Clofibrate	cancer	637-07-0	September 1, 1996
Clomiphene citrate	cancer	50-41-9	May 24, 2013
Clomiphene citrate	developmental	50-41-9	April 1, 1990
Clorazepate dipotassium	developmental	57109-90-7	October 1, 1992
CMNP (pyrazachlor)	cancer	6814-58-0	August 25, 2015
Cobalt metal powder	cancer	7440-48-4	July 1, 1992
Cobalt [II] oxide	cancer	1307-96-6	July 1, 1992
Cobalt sulfate	cancer	10124-43-3	May 20, 2005
Cobalt sulfate heptahydrate	cancer	10026-24-1	June 2, 2000
Cocaine	developmental, female	50-36-2	July 1, 1989
Coconut oil diethanolamine condensate (cocamide diethanolamine)	cancer	---	June 22, 2012
Codeine phosphate	developmental	52-28-8	May 15, 1998
Coke oven emissions	cancer	---	February 27, 1987
Colchicine	developmental, male	64-86-8	October 1, 1992
Conjugated estrogens	cancer	---	February 27, 1987
Conjugated estrogens	developmental	---	April 1, 1990
Creosotes	cancer	---	October 1, 1988
p-Cresidine	cancer	120-71-8	January 1, 1988
Cumene	cancer	98-82-8	April 6, 2010
Cupferron	cancer	135-20-6	January 1, 1988
Cyanazine	developmental	21725-46-2	April 1, 1990
Cycasin	cancer	14901-08-7	January 1, 1988
Cycloate	developmental	1134-23-2	March 19, 1999
<a href="#">Cyclohexanol, <u>Delisted January 25, 2002</u></a>	male	<a href="#">108-93-0</a>	<a href="#">November 6, 1998</a>
Cycloheximide	developmental	66-81-9	January 1, 1989
Cyclopenta[cd]pyrene	cancer	27208-37-3	April 29, 2011
Cyclophosphamide (anhydrous)	cancer	50-18-0	February 27, 1987
Cyclophosphamide (anhydrous)	developmental, female, male	50-18-0	January 1, 1989
Cyclophosphamide (hydrated)	cancer	6055-19-2	February 27, 1987
Cyclophosphamide (hydrated)	developmental, female, male	6055-19-2	January 1, 1989
Cyhexatin	developmental	13121-70-5	January 1, 1989
Cytarabine	developmental	147-94-4	January 1, 1989
Cytembena	cancer	21739-91-3	May 15, 1998
D&C Orange No. 17	cancer	3468-63-1	July 1, 1990
D&C Red No. 8	cancer	2092-56-0	October 1, 1990
D&C Red No. 9	cancer	5160-02-1	July 1, 1990
D&C Red No. 19	cancer	81-88-9	July 1, 1990
Dacarbazine	cancer	4342-03-4	January 1, 1988
Dacarbazine	developmental	4342-03-4	January 29, 1999
Daminozide	cancer	1596-84-5	January 1, 1990

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Danazol	developmental	17230-88-5	April 1, 1990
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	cancer	117-10-2	January 1, 1992
Daunomycin	cancer	20830-81-3	January 1, 1988
Daunorubicin hydrochloride	developmental	23541-50-6	July 1, 1990
2,4-D butyric acid	developmental, male	94-82-6	June 18, 1999
DDD (Dichlorodiphenyl-dichloroethane)	cancer	72-54-8	January 1, 1989
DDE (Dichlorodiphenyldichloroethylene)	cancer	72-55-9	January 1, 1989
DDT (Dichlorodiphenyltrichloroethane)	cancer	50-29-3	October 1, 1987
o,p'-DDT	developmental, female, male	789-02-6	May 15, 1998
p,p'-DDT	developmental, female, male	50-29-3	May 15, 1998
DDVP (Dichlorvos)	cancer	62-73-7	January 1, 1989
Demeclocycline hydrochloride (internal use)	developmental	64-73-3	January 1, 1992
Des-ethyl atrazine (DEA)	developmental, female	6190-65-4	July 15, 2016
Des-isopropyl atrazine (DIA)	developmental, female	1007-28-9	July 15, 2016
N,N'-Diacetylbenzidine	cancer	613-35-4	October 1, 1989
2,4-Diaminoanisole	cancer	615-05-4	October 1, 1990
2,4-Diaminoanisole sulfate	cancer	39156-41-7	January 1, 1988
2,4-Diamino-6-chloro-s-triazine (DACT)	developmental, female	3397-62-4	July 15, 2016
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	cancer	101-80-4	January 1, 1988
2,4-Diaminotoluene	cancer	95-80-7	January 1, 1988
<a href="#">Diaminotoluene (mixed), Delisted November 20, 2015</a>	<a href="#">cancer</a>	---	<a href="#">January 1, 1990</a>
Diazepam	developmental	439-14-5	January 1, 1992
Diazoaminobenzene	cancer	136-35-6	May 20, 2005
Diazoxide	developmental	364-98-7	February 27, 2001
Dibenz[a,h]acridine	cancer	226-36-8	January 1, 1988
Dibenz[a,j]acridine	cancer	224-42-0	January 1, 1988
Dibenzanthracenes	cancer	---	December 26, 2014
Dibenz[a,c]anthracene	cancer	215-58-7	December 26, 2014
Dibenz[a,h]anthracene	cancer	53-70-3	January 1, 1988
Dibenz[a,j]anthracene	cancer	224-41-9	December 26, 2014
7H-Dibenzo[c,g]carbazole	cancer	194-59-2	January 1, 1988
Dibenzo[a,e]pyrene	cancer	192-65-4	January 1, 1988
Dibenzo[a,h]pyrene	cancer	189-64-0	January 1, 1988
Dibenzo[a,i]pyrene	cancer	189-55-9	January 1, 1988
Dibenzo[a,l]pyrene	cancer	191-30-0	January 1, 1988
Dibromoacetic acid	cancer	631-64-1	June 17, 2008
Dibromoacetonitrile	cancer	3252-43-5	May 3, 2011
1,2-Dibromo-3-chloropropane (DBCP)	cancer	96-12-8	July 1, 1987
1,2-Dibromo-3-chloropropane (DBCP)	male	96-12-8	February 27, 1987
2,3-Dibromo-1-propanol	cancer	96-13-9	October 1, 1994
Di-n-butyl phthalate (DBP)	developmental, female, male	84-74-2	December 2, 2005
Dichloroacetic acid	cancer	79-43-6	May 1, 1996
Dichloroacetic acid	developmental, male	79-43-6	August 7, 2009

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
<i>p</i> -Dichlorobenzene	cancer	106-46-7	January 1, 1989
3,3'-Dichlorobenzidine	cancer	91-94-1	October 1, 1987
3,3'-Dichlorobenzidine dihydrochloride	cancer	612-83-9	May 15, 1998
1,1-Dichloro-2,2-bis( <i>p</i> -chlorophenyl)ethylene (DDE)	developmental, male	72-55-9	March 30, 2010
1,4-Dichloro-2-butene	cancer	764-41-0	January 1, 1990
3,3'-Dichloro-4,4'-diaminodiphenyl ether	cancer	28434-86-8	January 1, 1988
1,1-Dichloroethane	cancer	75-34-3	January 1, 1990
Dichloromethane (Methylene chloride)	cancer	75-09-2	April 1, 1988
1,4-Dichloro-2-nitrobenzene	cancer	89-61-2	September 13, 2019
2,4-Dichloro-1-nitrobenzene	cancer	611-06-3	September 13, 2019
Dichlorophene	developmental	97-23-4	April 27, 1999
1,2-Dichloropropane	cancer	78-87-5	January 1, 1990
1,3-Dichloro-2-propanol (1,3-DCP)	cancer	96-23-1	October 8, 2010
1,3-Dichloropropene	cancer	542-75-6	January 1, 1989
Dichlorophenamide	developmental	120-97-8	February 27, 2001
Diclofop-methyl	cancer	51338-27-3	April 6, 2010
Diclofop methyl	developmental	51338-27-3	March 5, 1999
Dicumarol	developmental	66-76-2	October 1, 1992
Dieldrin	cancer	60-57-1	July 1, 1988
<a href="#">Dienestrol, Delisted January 4, 2013</a>	<a href="#">cancer</a>	<a href="#">84-17-3</a>	<a href="#">January 1, 1990</a>
Diepoxybutane	cancer	1464-53-5	January 1, 1988
Diesel engine exhaust	cancer	---	October 1, 1990
Diethanolamine	cancer	111-42-2	June 22, 2012
Di(2-ethylhexyl)phthalate (DEHP)	cancer	117-81-7	January 1, 1988
Di(2-ethylhexyl)phthalate (DEHP)	developmental, male	117-81-7	October 24, 2003
1,2-Diethylhydrazine	cancer	1615-80-1	January 1, 1988
Diethylstilbestrol (DES)	cancer	56-53-1	February 27, 1987
Diethylstilbestrol (DES)	developmental	56-53-1	July 1, 1987
Diethyl sulfate	cancer	64-67-5	January 1, 1988
Diflunisal	developmental, female	22494-42-4	January 29, 1999
<a href="#">Diglycidyl ether, Delisted April 4, 2014</a>	<a href="#">male</a>	<a href="#">2238-07-5</a>	<a href="#">August 7, 2009</a>
Diglycidyl resorcinol ether (DGRE)	cancer	101-90-6	July 1, 1989
Di- <i>n</i> -hexyl phthalate (DnHP)	female, male	84-75-3	December 2, 2005
Dihydroergotamine mesylate	developmental	6190-39-2	May 1, 1997
Dihydrosafrole	cancer	94-58-6	January 1, 1988
Di-isodecyl phthalate (DIDP)	developmental	68515-49-1/26761-40-0	April 20, 2007
Diisononyl phthalate (DINP)	cancer	---	December 20, 2013
Diisopropyl sulfate	cancer	2973-10-6	April 1, 1993
Diltiazem hydrochloride	developmental	33286-22-5	February 27, 2001
3,3'-Dimethoxybenzidine ( <i>o</i> -Dianisidine)	cancer	119-90-4	January 1, 1988
3,3'-Dimethoxybenzidine dihydrochloride	cancer	20325-40-0	October 1, 1990
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine	cancer	---	June 11, 2004
N,N-Dimethylacetamide	cancer	127-19-5	September 13, 2019
N,N-Dimethylacetamide	developmental, male	127-19-5	May 21, 2010
4-Dimethylaminoazobenzene	cancer	60-11-7	January 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
<i>trans</i> -2-[(Dimethylamino)methyl- imino]-5-[2-(5-nitro-2-furyl)vinyl]- 1,3,4-oxadiazole	cancer	55738-54-0	January 1, 1988
7,12-Dimethylbenz(a)anthracene	cancer	57-97-6	January 1, 1990
3,3'-Dimethylbenzidine (ortho- Tolidine)	cancer	119-93-7	January 1, 1988
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'- dimethylbenzidine	cancer	---	June 11, 2004
3,3'-Dimethylbenzidine dihydrochloride	cancer	612-82-8	April 1, 1992
Dimethylcarbamoyl chloride	cancer	79-44-7	January 1, 1988
N,N-Dimethylformamide	cancer	68-12-2	October 27, 2017
1,1-Dimethylhydrazine (UDMH)	cancer	57-14-7	October 1, 1989
1,2-Dimethylhydrazine	cancer	540-73-8	January 1, 1988
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	cancer	1456-28-6	February 8, 2013
Dimethyl sulfate	cancer	77-78-1	January 1, 1988
<i>N,N</i> -Dimethyl- <i>p</i> -toluidine	cancer	99-97-8	May 2, 2014
Dimethylvinylchloride	cancer	513-37-1	July 1, 1989
<i>m</i> -Dinitrobenzene	male	99-65-0	July 1, 1990
<i>o</i> -Dinitrobenzene	male	528-29-0	July 1, 1990
<i>p</i> -Dinitrobenzene	male	100-25-4	July 1, 1990
3,7-Dinitrofluoranthene	cancer	105735-71-5	August 26, 1997
3,9-Dinitrofluoranthene	cancer	22506-53-2	August 26, 1997
1,3-Dinitropyrene	cancer	75321-20-9	November 2, 2012
1,6-Dinitropyrene	cancer	42397-64-8	October 1, 1990
1,8-Dinitropyrene	cancer	42397-65-9	October 1, 1990
Dinitrotoluene (technical grade)	female, male	---	August 20, 1999
2,4-Dinitrotoluene	cancer	121-14-2	July 1, 1988
2,4-Dinitrotoluene	male	121-14-2	August 20, 1999
2,6-Dinitrotoluene	cancer	606-20-2	July 1, 1995
2,6-Dinitrotoluene	male	606-20-2	August 20, 1999
Dinitrotoluene mixture, 2,4-/2,6-	cancer	---	May 1, 1996
Dinocap	developmental	39300-45-3	April 1, 1990
Dinoseb	developmental, male	88-85-7	January 1, 1989
Di- <i>n</i> -propyl isocinchomeronate (MGK Repellent 326)	cancer	136-45-8	May 1, 1996
1,4-Dioxane	cancer	123-91-1	January 1, 1988
Diphenylhydantoin (Phenytoin)	cancer	57-41-0	January 1, 1988
Diphenylhydantoin (Phenytoin)	developmental	57-41-0	July 1, 1987
Diphenylhydantoin (Phenytoin), sodium salt	cancer	630-93-3	January 1, 1988
Direct Black 38 (technical grade)	cancer	1937-37-7	January 1, 1988
Direct Blue 6 (technical grade)	cancer	2602-46-2	January 1, 1988
Direct Brown 95 (technical grade)	cancer	16071-86-6	October 1, 1988
Disodium cyanodithioimido- carbonate	developmental	138-93-2	March 30, 1999
Disperse Blue 1	cancer	2475-45-8	October 1, 1990
Diuron	cancer	330-54-1	May 31, 2002
Doxorubicin hydrochloride (Adriamycin)	cancer	25316-40-9	July 1, 1987
Doxorubicin hydrochloride (Adriamycin)	developmental, male	25316-40-9	January 29, 1999
Doxycycline (internal use)	developmental	564-25-0	July 1, 1990
Doxycycline calcium (internal use)	developmental	94088-85-4	January 1, 1992

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Doxycycline hyclate (internal use)	developmental	24390-14-5	October 1, 1991
Doxycycline monohydrate (internal use)	developmental	17086-28-1	October 1, 1991
<a href="#">2,4-DP (dichloroprop), Delisted January 25, 2002</a>	<a href="#">developmental</a>	<a href="#">120-36-5</a>	<a href="#">April 27, 1999</a>
Emissions from combustion of coal	cancer	---	August 7, 2013
Emissions from high-temperature unrefined rapeseed oil	cancer	---	January 3, 2014
Endrin	developmental	72-20-8	May 15, 1998
Environmental tobacco smoke (ETS)	developmental	---	June 9, 2006
Epichlorohydrin	cancer	106-89-8	October 1, 1987
Epichlorohydrin	male	106-89-8	September 1, 1996
Epoxiconazole	cancer	135319-73-2	April 15, 2011
Ergotamine tartrate	developmental	379-79-3	April 1, 1990
Erionite	cancer	12510-42-8/66733-21-9	October 1, 1988
Estradiol 17B	cancer	50-28-2	January 1, 1988
Estragole	cancer	140-67-0	October 29, 1999
Estrogens, steroidal	cancer	---	August 19, 2005
Estrogen-progestogen (combined) used as menopausal therapy	cancer	---	November 4, 2011
Estrone	cancer	53-16-7	January 1, 1988
Estropipate	cancer, developmental	7280-37-7	August 26, 1997
Ethinylestradiol	cancer	57-63-6	January 1, 1988
Ethionamide	developmental	536-33-4	August 26, 1997
Ethoprop	cancer	13194-48-4	February 27, 2001
Ethyl acrylate	cancer	140-88-5	July 1, 1989
Ethyl alcohol in alcoholic beverages	developmental	---	October 1, 1987
Ethylbenzene	cancer	100-41-4	June 11, 2004
<a href="#">Ethyl tert-butyl ether, Delisted December 13, 2013</a>	<a href="#">male</a>	<a href="#">637-92-3</a>	<a href="#">December 18, 2009</a>
Ethyl dipropylthiocarbamate	developmental	759-94-4	April 27, 1999
Ethyl-4,4'-dichlorobenzilate	cancer	510-15-6	January 1, 1990
Ethylene dibromide	cancer	106-93-4	July 1, 1987
Ethylene dibromide	developmental, male	106-93-4	May 15, 1998
Ethylene dichloride (1,2-Dichloroethane)	cancer	107-06-2	October 1, 1987
Ethylene glycol (ingested)	developmental	107-21-1	June 19, 2015
Ethylene glycol monoethyl ether	developmental, male	110-80-5	January 1, 1989
Ethylene glycol monoethyl ether acetate	developmental, male	111-15-9	January 1, 1993
Ethylene glycol monomethyl ether	developmental, male	109-86-4	January 1, 1989
Ethylene glycol monomethyl ether acetate	developmental, male	110-49-6	January 1, 1993
Ethyleneimine (Aziridine)	cancer	151-56-4	January 1, 1988
Ethylene oxide	cancer	75-21-8	July 1, 1987
Ethylene oxide	female	75-21-8	February 27, 1987
Ethylene oxide	developmental, male	75-21-8	August 7, 2009
Ethylene thiourea	cancer	96-45-7	January 1, 1988
Ethylene thiourea	developmental	96-45-7	January 1, 1993
<a href="#">2-Ethylhexanoic acid, Delisted December 13, 2013</a>	<a href="#">developmental</a>	<a href="#">149-57-5</a>	<a href="#">August 7, 2009</a>
2-Ethylhexyl acrylate	cancer	103-11-7	December 17, 2021
Ethyl methanesulfonate	cancer	62-50-0	January 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Etodolac	developmental, female	41340-25-4	August 20, 1999
Etoposide	cancer	33419-42-0	November 4, 2011
Etoposide	developmental	33419-42-0	July 1, 1990
Etoposide in combination with cisplatin and bleomycin	cancer	---	November 4, 2011
Etretinate	developmental	54350-48-0	July 1, 1987
Fenoxaprop ethyl	developmental	66441-23-4	March 26, 1999
Fenoxycarb	cancer	72490-01-8	June 2, 2000
Filgrastim	developmental	121181-53-1	February 27, 2001
Fluazifop butyl	developmental	69806-50-4	November 6, 1998
Flunisolide	developmental, female	3385-03-3	May 15, 1998
Fluorouracil	developmental	51-21-8	January 1, 1989
Fluoxymesterone	developmental	76-43-7	April 1, 1990
Flurazepam hydrochloride	developmental	1172-18-5	October 1, 1992
Flurbiprofen	developmental, female	5104-49-4	August 20, 1999
Flutamide	developmental	13311-84-7	July 1, 1990
Fluticasone propionate	developmental	80474-14-2	May 15, 1998
Fluvalinate	developmental	69409-94-5	November 6, 1998
Folpet	cancer	133-07-3	January 1, 1989
Formaldehyde (gas)	cancer	50-00-0	January 1, 1988
2-(2-Formylhydrazino)-4-(5-nitro-2- furyl)thiazole	cancer	3570-75-0	January 1, 1988
Fumonisin B <sub>1</sub>	cancer	116355-83-0	November 14, 2003
Furan	cancer	110-00-9	October 1, 1993
Furazolidone	cancer	67-45-8	January 1, 1990
Furfuryl alcohol	cancer	98-00-0	September 30, 2016
Furmecyclox	cancer	60568-05-0	January 1, 1990
Fusarin C	cancer	79748-81-5	July 1, 1995
Gallium arsenide	cancer	1303-00-0	August 1, 2008
Ganciclovir	cancer, developmental, male	82410-32-0	August 26, 1997
Ganciclovir sodium	developmental, male	107910-75-8	August 26, 1997
Gasoline engine exhaust (condensates/extracts)	cancer	---	October 1, 1990
Gemfibrozil	cancer	25812-30-0	December 22, 2000
Gemfibrozil	female, male	25812-30-0	August 20, 1999
Gentian violet (Crystal violet)	cancer	548-62-9	November 23, 2018
Glass wool fibers (inhalable and biopersistent)	cancer	---	July 1, 1990
Glu-P-1 (2-Amino-6-methyldipyrido [1,2- a:3',2'-d]imidazole)	cancer	67730-11-4	January 1, 1990
Glu-P-2 (2-Aminodipyrido [1,2- a:3',2'-d]imidazole)	cancer	67730-10-3	January 1, 1990
Glycidaldehyde	cancer	765-34-4	January 1, 1988
Glycidol	cancer	556-52-5	July 1, 1990
Glycidyl methacrylate	cancer	106-91-2	January 27, 2023
Glyphosate	cancer	1071-83-6	July 7, 2017
Goldenseal root powder	cancer	---	December 4, 2015
Goserelin acetate	developmental, female, male	65807-02-5	August 26, 1997
Griseofulvin	cancer	126-07-8	January 1, 1990
Gyromitrin (Acetaldehyde methylformylhydrazone)	cancer	16568-02-8	January 1, 1988



<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Halazepam	developmental	23092-17-3	July 1, 1990
Halobetasol propionate	developmental	66852-54-8	August 20, 1999
Haloperidol	developmental, female	52-86-8	January 29, 1999
Halothane	developmental	151-67-7	September 1, 1996
HC Blue 1	cancer	2784-94-3	July 1, 1989
Heptachlor	cancer	76-44-8	July 1, 1988
Heptachlor	developmental	76-44-8	August 20, 1999
Heptachlor epoxide	cancer	1024-57-3	July 1, 1988
Herbal remedies containing plant species of the genus <i>Aristolochia</i>	cancer	---	July 9, 2004
Hexachlorobenzene	cancer	118-74-1	October 1, 1987
Hexachlorobenzene	developmental	118-74-1	January 1, 1989
Hexachlorobutadiene	cancer	87-68-3	May 3, 2011
Hexachlorocyclohexane (technical grade)	cancer	---	October 1, 1987
Hexachlorodibenzodioxin	cancer	34465-46-8	April 1, 1988
Hexachloroethane	cancer	67-72-1	July 1, 1990
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	cancer	---	March 4, 2005
Hexafluoroacetone	developmental, male	684-16-2	August 1, 2008
Hexamethylphosphoramide	cancer	680-31-9	January 1, 1988
Hexamethylphosphoramide	male	680-31-9	October 1, 1994
<i>n</i> -Hexane	male	110-54-3	December 15, 2017
2,5-Hexanedione	male	110-13-4	December 4, 2015
Histrelin acetate	developmental	---	May 15, 1998
Hydramethylnon	developmental, male	67485-29-4	March 5, 1999
Hydrazine	cancer	302-01-2	January 1, 1988
Hydrazine sulfate	cancer	10034-93-2	January 1, 1988
Hydrazobenzene (1,2-Diphenylhydrazine)	cancer	122-66-7	January 1, 1988
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male	---	July 5, 2013
1-Hydroxyanthraquinone	cancer	129-43-1	May 27, 2005
Hydroxyurea	developmental	127-07-1	May 1, 1997
Idarubicin hydrochloride	developmental, male	57852-57-0	August 20, 1999
Ifosfamide	developmental	3778-73-2	July 1, 1990
Iodine-131	developmental	10043-66-0	January 1, 1989
Imazalil	cancer	35554-44-0	May 20, 2011
Indeno[1,2,3-cd]pyrene	cancer	193-39-5	January 1, 1988
Indium phosphide	cancer	22398-80-7	February 27, 2001
Indium tin oxide	cancer	50926-11-9	March 19, 2021
IQ (2-Amino-3-methylimidazo [4,5-f] quinoline)	cancer	76180-96-6	April 1, 1990
Iprodione	cancer	36734-19-7	May 1, 1996
Iprovalicarb	cancer	140923-17-7/ 140923-25-7	June 1, 2007
Iron dextran complex	cancer	9004-66-4	January 1, 1988
Isobutyl nitrite	cancer	542-56-3	May 1, 1996
Isoprene	cancer	78-79-5	May 1, 1996
Isopyrazam	cancer	881685-58-1	July 24, 2012
<a href="#">Isosafrole, Delisted December 8, 2006</a>	<a href="#">cancer</a>	<a href="#">420-58-4</a>	<a href="#">October 1, 1989</a>
Isotretinoin	developmental	4759-48-2	July 1, 1987
Isoxaflutole	cancer	141112-29-0	December 22, 2000

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Kresoxim-methyl	cancer	143390-89-0	February 3, 2012
Lactofen	cancer	77501-63-4	January 1, 1989
Lasiocarpine	cancer	303-34-4	April 1, 1988
Lead	developmental, female, male	---	February 27, 1987
Lead and lead compounds	cancer	---	October 1, 1992
Lead acetate	cancer	301-04-2	January 1, 1988
Lead phosphate	cancer	7446-27-7	April 1, 1988
Lead subacetate	cancer	1335-32-6	October 1, 1989
Leather dust	cancer	---	April 29, 2011
Leucomalachite green	cancer	129-73-7	April 21, 2023
Leuprolide acetate	developmental, female, male	74381-53-6	August 26, 1997
Levodopa	developmental	59-92-7	January 29, 1999
Levonorgestrel implants	female	797-63-7	May 15, 1998
Lindane and other hexachloro- cyclohexane isomers	cancer	---	October 1, 1989
Linuron	developmental	330-55-2	March 19, 1999
Lithium carbonate	developmental	554-13-2	January 1, 1991
Lithium citrate	developmental	919-16-4	January 1, 1991
Lorazepam	developmental	846-49-1	July 1, 1990
Lovastatin	developmental	75330-75-5	October 1, 1992
Lynestrenol	cancer	52-76-6	February 27, 2001
Malathion	cancer	121-75-5	May 20, 2016
Malonaldehyde, sodium salt	cancer	24382-04-5	May 3, 2011
Mancozeb	cancer	8018-01-7	January 1, 1990
Maneb	cancer	12427-38-2	January 1, 1990
Marijuana smoke	cancer	---	June 19, 2009
Me-A-alpha-C (2-Amino-3-methyl- 9H-pyrido[2,3-b]indole)	cancer	68006-83-7	January 1, 1990
Mebendazole	developmental	31431-39-7	August 20, 1999
Medroxyprogesterone acetate	cancer	71-58-9	January 1, 1990
Medroxyprogesterone acetate	developmental	71-58-9	April 1, 1990
Megestrol acetate	cancer	595-33-5	March 28, 2014
Megestrol acetate	developmental	595-33-5	January 1, 1991
MelQ (2-Amino-3,4-dimethyl- imidazo[4,5-f]quinoline)	cancer	77094-11-2	October 1, 1994
MelQx (2-Amino-3,8-dimethyl- imidazo[4,5-f]quinoxaline)	cancer	77500-04-0	October 1, 1994
Melphalan	cancer	148-82-3	February 27, 1987
Melphalan	developmental	148-82-3	July 1, 1990
Menotropins	developmental	9002-68-0	April 1, 1990
Mepaniprim	cancer	110235-47-7	July 1, 2008
Meproamate	developmental	57-53-4	January 1, 1992
2-Mercaptobenzothiazole	cancer	149-30-4	October 27, 2017
Mercaptopurine	developmental	6112-76-1	July 1, 1990
Mercury and mercury compounds	developmental	---	July 1, 1990
Merphalan	cancer	531-76-0	April 1, 1988
Mestranol	cancer	72-33-3	April 1, 1988
Metam potassium	cancer	137-41-7	December 31, 2010
Methacycline hydrochloride	developmental	3963-95-9	January 1, 1991
Metham sodium	cancer	137-42-8	November 6, 1998
Metham sodium	developmental	137-42-8	May 15, 1998

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Methanol	developmental	67-56-1	March 16, 2012
Methazole	developmental	20354-26-1	December 1, 1999
Methimazole	developmental	60-56-0	July 1, 1990
Methotrexate	developmental	59-05-2	January 1, 1989
Methotrexate sodium	developmental	15475-56-6	April 1, 1990
5-Methoxypsoralen with ultraviolet A therapy	cancer	484-20-8	October 1, 1988
8-Methoxypsoralen with ultraviolet A therapy	cancer	298-81-7	February 27, 1987
Methyl acrylate	cancer	96-33-3	December 17, 2021
2-Methylaziridine (Propyleneimine)	cancer	75-55-8	January 1, 1988
Methylazoxymethanol	cancer	590-96-5	April 1, 1988
Methylazoxymethanol acetate	cancer	592-62-1	April 1, 1988
Methyl bromide, as a structural fumigant	developmental	74-83-9	January 1, 1993
Methyl carbamate	cancer	598-55-0	May 15, 1998
Methyl chloride	developmental	74-87-3	March 10, 2000
Methyl chloride	male	74-87-3	August 7, 2009
3-Methylcholanthrene	cancer	56-49-5	January 1, 1990
5-Methylchrysene	cancer	3697-24-3	April 1, 1988
4,4'-Methylene bis(2-chloroaniline)	cancer	101-14-4	July 1, 1987
4,4'-Methylene bis(N,N-dimethyl benzenamine)	cancer	101-61-1	October 1, 1989
4,4'-Methylene bis(2-methylaniline)	cancer	838-88-0	April 1, 1988
4,4'-Methylenedianiline	cancer	101-77-9	January 1, 1988
4,4'-Methylenedianiline dihydrochloride	cancer	13552-44-8	January 1, 1988
Methyleugenol	cancer	93-15-2	November 16, 2001
Methylhydrazine and its salts	cancer	---	July 1, 1992
2-Methylimidazole	cancer	693-98-1	June 22, 2012
4-Methylimidazole	cancer	822-36-6	January 7, 2011
Methyl iodide	cancer	74-88-4	April 1, 1988
Methyl isobutyl ketone	cancer	108-10-1	November 4, 2011
Methyl isobutyl ketone (MIBK)	developmental	108-10-1	March 28, 2014
Methyl isocyanate (MIC)	developmental, female	624-83-9	November 12, 2010
<a href="#">Methyl isopropyl ketone, Delisted April 4, 2014</a>	<a href="#">developmental</a>	<a href="#">563-80-4</a>	<a href="#">February 17, 2012</a>
Methyl mercury	developmental	---	July 1, 1987
Methylmercury compounds	cancer	---	May 1, 1996
Methyl methanesulfonate	cancer	66-27-3	April 1, 1988
Methyl-n-butyl ketone	male	591-78-6	August 7, 2009
Methyl-n-butyl ketone	developmental	591-78-6	December 4, 2015
2-Methyl-1-nitroanthraquinone (of uncertain purity)	cancer	129-15-7	April 1, 1988
N-Methyl-N'-nitro-N-nitrosoguanidine	cancer	70-25-7	April 1, 1988
N-Methylolacrylamide	cancer	924-42-5	July 1, 1990
N-Methylpyrrolidone	developmental	872-50-4	June 15, 2001
α-Methyl styrene (alpha-Methylstyrene)	cancer	98-83-9	November 2, 2012
<a href="#">α-Methyl styrene, Delisted April 4, 2014</a>	<a href="#">female</a>	<a href="#">98-83-9</a>	<a href="#">July 29, 2011</a>
Methyltestosterone	developmental	58-18-4	April 1, 1990
Methylthiouracil	cancer	56-04-2	October 1, 1989
Metiram	cancer	9006-42-2	January 1, 1990
Metiram	developmental	9006-42-2	March 30, 1999

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Metronidazole	cancer	443-48-1	January 1, 1988
Michler's ketone	cancer	90-94-8	January 1, 1988
Midazolam hydrochloride	developmental	59467-96-8	July 1, 1990
Minocycline hydrochloride (internal use)	developmental	13614-98-7	January 1, 1992
Mirex	cancer	2385-85-5	January 1, 1988
Misoprostol	developmental	59122-46-2	April 1, 1990
Mitomycin C	cancer	50-07-7	April 1, 1988
Mitoxantrone hydrochloride	cancer	70476-82-3	January 23, 2015
Mitoxantrone hydrochloride	developmental	70476-82-3	July 1, 1990
Molinate	developmental, female, male	2212-67-1	December 11, 2009
Molybdenum trioxide	cancer	1313-27-5	March 19, 2021
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane)	cancer	71526-07-3	March 22, 2011
MON 13900 (furilazole)	cancer	121776-33-8	March 22, 2011
3-Monochloropropane-1,2-diol (3-MCPD)	cancer	96-24-2	October 8, 2010
Monocrotaline	cancer	315-22-0	April 1, 1988
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	cancer	113803-47-7	November 4, 2011
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)-amino]-2-oxazolidinone	cancer	139-91-3	April 1, 1988
Mustard Gas	cancer	505-60-2	February 27, 1987
MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone)	cancer	77439-76-0	December 22, 2000
Myclobutanil	developmental, male	88671-89-0	April 16, 1999
beta-Myrcene	cancer	123-35-3	March 27, 2015
Nabam	developmental	142-59-6	March 30, 1999
Nafarelin acetate	developmental	86220-42-0	April 1, 1990
Nafenopin	cancer	3771-19-5	April 1, 1988
Nalidixic acid	cancer	389-08-2	May 15, 1998
Naphthalene	cancer	91-20-3	April 19, 2002
1-Naphthylamine	cancer	134-32-7	October 1, 1989
2-Naphthylamine	cancer	91-59-8	February 27, 1987
Neomycin sulfate (internal use)	developmental	1405-10-3	October 1, 1992
Netilmicin sulfate	developmental	56391-57-2	July 1, 1990
Nickel (Metallic)	cancer	7440-02-0	October 1, 1989
Nickel acetate	cancer	373-02-4	October 1, 1989
Nickel carbonate	cancer	3333-67-3	October 1, 1989
Nickel carbonyl	cancer	13463-39-3	October 1, 1987
Nickel carbonyl	developmental	13463-39-3	September 1, 1996
Nickel compounds	cancer	---	May 7, 2004
Nickel (soluble compounds)	developmental, male	---	October 26, 2018
Nickel hydroxide	cancer	12054-48-7; 12125-56-3	October 1, 1989
Nickelocene	cancer	1271-28-9	October 1, 1989
Nickel oxide	cancer	1313-99-1	October 1, 1989
Nickel refinery dust from the pyrometallurgical process	cancer	---	October 1, 1987
Nickel subsulfide	cancer	12035-72-2	October 1, 1987
Nicotine	developmental	54-11-5	April 1, 1990

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Nifedipine	developmental, female, male	21829-25-4	January 29, 1999
Nimodipine	developmental	66085-59-4	April 24, 2001
Niridazole	cancer	61-57-4	April 1, 1988
Nitrapyrin	cancer	1929-82-4	October 5, 2005
Nitrapyrin	developmental	1929-82-4	March 30, 1999
Nitrilotriacetic acid	cancer	139-13-9	January 1, 1988
Nitrilotriacetic acid, trisodium salt monohydrate	cancer	18662-53-8	April 1, 1989
5-Nitroacenaphthene	cancer	602-87-9	April 1, 1988
<del>5-Nitro-<i>o</i>-anisidine, Delisted December 8, 2006</del>	<del>cancer</del>	<del>99-59-2</del>	<del>October 1, 1989</del>
<i>o</i> -Nitroanisole	cancer	91-23-6	October 1, 1992
<i>para</i> -Nitroanisole	cancer	100-17-4	September 13, 2019
Nitrobenzene	cancer	98-95-3	August 26, 1997
Nitrobenzene	male	98-95-3	March 30, 2010
4-Nitrobiphenyl	cancer	92-93-3	April 1, 1988
6-Nitrochrysene	cancer	7496-02-8	October 1, 1990
Nitrofen (technical grade)	cancer	1836-75-5	January 1, 1988
2-Nitrofluorene	cancer	607-57-8	October 1, 1990
Nitrofurantoin	male	67-20-9	April 1, 1991
Nitrofurazone	cancer	59-87-0	January 1, 1990
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	cancer	555-84-0	April 1, 1988
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	cancer	531-82-8	April 1, 1988
Nitrogen mustard (Mechlorethamine)	cancer	51-75-2	January 1, 1988
Nitrogen mustard (Mechlorethamine)	developmental	51-75-2	January 1, 1989
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	cancer	55-86-7	April 1, 1988
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	55-86-7	July 1, 1990
Nitrogen mustard N-oxide	cancer	126-85-2	April 1, 1988
Nitrogen mustard N-oxide hydrochloride	cancer	302-70-5	April 1, 1988
Nitromethane	cancer	75-52-5	May 1, 1997
2-Nitropropane	cancer	79-46-9	January 1, 1988
1-Nitropyrene	cancer	5522-43-0	October 1, 1990
4-Nitropyrene	cancer	57835-92-4	October 1, 1990
N-Nitrosodi- <i>n</i> -butylamine	cancer	924-16-3	October 1, 1987
N-Nitrosodiethanolamine	cancer	1116-54-7	January 1, 1988
N-Nitrosodiethylamine	cancer	55-18-5	October 1, 1987
N-Nitrosodimethylamine	cancer	62-75-9	October 1, 1987
<i>p</i> -Nitrosodiphenylamine	cancer	156-10-5	January 1, 1988
N-Nitrosodiphenylamine	cancer	86-30-6	April 1, 1988
N-Nitrosodi- <i>n</i> -propylamine	cancer	621-64-7	January 1, 1988
N-Nitroso-N-ethylurea	cancer	759-73-9	October 1, 1987
N-Nitrosohexamethyleneimine	cancer	932-83-2	November 23, 2018
3-(N-Nitrosomethylamino)-propionitrile	cancer	60153-49-3	April 1, 1990
4-(N-Nitrosomethylamino)-1-(3-pyridyl)1-butanone	cancer	64091-91-4	April 1, 1990
N-Nitrosomethyl- <i>n</i> -butylamine	cancer	7068-83-9	December 26, 2014
N-Nitrosomethyl- <i>n</i> -decylamine	cancer	75881-22-0	December 26, 2014

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
N-Nitrosomethyl- <i>n</i> -dodecylamine	cancer	55090-44-3	December 26, 2014
N-Nitrosomethylethylamine	cancer	10595-95-6	October 1, 1989
N-Nitrosomethyl- <i>n</i> -heptylamine	cancer	16338-99-1	December 26, 2014
N-Nitrosomethyl- <i>n</i> -hexylamine	cancer	28538-70-7	December 26, 2014
N-Nitrosomethyl- <i>n</i> -nonylamine	cancer	75881-19-5	December 26, 2014
N-Nitrosomethyl- <i>n</i> -octylamine	cancer	34423-54-6	December 26, 2014
N-Nitrosomethyl- <i>n</i> -pentylamine	cancer	13256-07-0	December 26, 2014
N-Nitrosomethyl- <i>n</i> -propylamine	cancer	924-46-9	December 26, 2014
N-Nitrosomethyl- <i>n</i> -tetradecylamine	cancer	75881-20-8	December 26, 2014
N-Nitrosomethyl- <i>n</i> -undecylamine	cancer	68107-26-6	December 26, 2014
N-Nitroso-N-methylurea	cancer	684-93-5	October 1, 1987
N-Nitroso-N-methylurethane	cancer	615-53-2	April 1, 1988
N-Nitrosomethylvinylamine	cancer	4549-40-0	January 1, 1988
N-Nitrosomorpholine	cancer	59-89-2	January 1, 1988
N-Nitrosornicotine	cancer	16543-55-8	January 1, 1988
N-Nitrosopiperidine	cancer	100-75-4	January 1, 1988
N-Nitrosopyrrolidine	cancer	930-55-2	October 1, 1987
N-Nitrososarcosine	cancer	13256-22-9	January 1, 1988
<i>o</i> -Nitrotoluene	cancer	88-72-2	May 15, 1998
Nitrous oxide	developmental, female	10024-97-2	August 1, 2008
Norethisterone (Norethindrone)	cancer	68-22-4	October 1, 1989
Norethisterone (Norethindrone)	developmental	68-22-4	April 1, 1990
Norethisterone acetate (Norethindrone acetate)	developmental	51-98-9	October 1, 1991
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	68-22-4 / 57- 63-6	April 1, 1990
Norethisterone(Norethindrone)/ Mestranol	developmental	68-22-4 / 72- 33-3	April 1, 1990
Norethynodrel	cancer	68-23-5	February 27, 2001
Norgestrel	developmental	6533-00-2	April 1, 1990
Ochratoxin A	cancer	303-47-9	July 1, 1990
Oil Orange SS	cancer	2646-17-5	April 1, 1988
Oral contraceptives, combined	cancer	---	October 1, 1989
Oral contraceptives, sequential	cancer	---	October 1, 1989
Oryzalin	cancer	19044-88-3	September 12, 2008
Oxadiazon	cancer	19666-30-9	July 1, 1991
Oxadiazon	developmental	19666-30-9	May 15, 1998
Oxazepam	cancer	604-75-1	October 1, 1994
Oxazepam	developmental	604-75-1	October 1, 1992
<a href="#">p,p'-Oxybis(benzenesulfonyl hydrazide)</a> , <a href="#">Delisted December 13, 2013</a>	<a href="#">developmental</a>	<a href="#">80-51-3</a>	<a href="#">August 7, 2009</a>
Oxydemeton methyl	female, male	301-12-2	November 6, 1998
Oxymetholone	cancer	434-07-1	January 1, 1988
Oxymetholone	developmental	434-07-1	May 1, 1997
Oxytetracycline (internal use)	developmental	79-57-2	January 1, 1991
Oxytetracycline hydrochloride (internal use)	developmental	2058-46-0	October 1, 1991
Oxythioquinox (Chinomethionat)	cancer	2439-01-2	August 20, 1999
Oxythioquinox (Chinomethionat)	developmental	2439-01-2	November 6, 1998
Paclitaxel	developmental, female, male	33069-62-4	August 26, 1997
Palygorskite fibers (> 5µm in length)	cancer	12174-11-7	December 28, 1999
Panfuran S	cancer	794-93-4	January 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Paramethadione	developmental	115-67-3	July 1, 1990
Parathion	cancer	56-38-2	May 20, 2016
Penicillamine	developmental	52-67-5	January 1, 1991
Pentabromodiphenyl ether mixture [DE-71 (technical grade)]	cancer	---	July 7, 2017
Pentachlorophenol	cancer	87-86-5	January 1, 1990
Pentachlorophenol and by-products of its synthesis (complex mixture)	cancer	---	October 21, 2016
Pentobarbital sodium	developmental	57-33-0	July 1, 1990
Pentosan polysulfate sodium	cancer	---	April 18, 2014
Pentostatin	developmental	53910-25-1	September 1, 1996
Perfluorononanoic acid (PFNA) and its salts	male	---	December 31, 2021
Perfluorooctane sulfonate (PFOS)	developmental	1763-23-1	November 10, 2017
Perfluorooctane sulfonic acid (PFOS) and its salts and transformation and degradation precursors	cancer	---	December 24, 2021
Perfluorooctanoic acid (PFOA)	cancer	335-67-1	February 25, 2022
Perfluorooctanoic acid (PFOA)	developmental	335-67-1	November 10, 2017
Pertuzumab	developmental	380610-27-5	January 27, 2017
Phenacemide	developmental	63-98-9	July 1, 1990
Phenacetin	cancer	62-44-2	October 1, 1989
Phenazopyridine	cancer	94-78-0	January 1, 1988
Phenazopyridine hydrochloride	cancer	136-40-3	January 1, 1988
Phenesterin	cancer	3546-10-9	July 1, 1989
Phenobarbital	cancer	50-06-6	January 1, 1990
Phenolphthalein	cancer	77-09-8	May 15, 1998
Phenoxybenzamine	cancer	59-96-1	April 1, 1988
Phenoxybenzamine hydrochloride	cancer	63-92-3	April 1, 1988
Phenprocoumon	developmental	435-97-2	October 1, 1992
o-Phenylenediamine and its salts	cancer	95-54-5	May 15, 1998
Phenyl glycidyl ether	cancer	122-60-1	October 1, 1990
<a href="#">Phenyl glycidyl ether, Delisted April 4, 2014</a>	male	<a href="#">122-60-1</a>	<a href="#">August 7, 2009</a>
Phenylhydrazine and its salts	cancer	---	July 1, 1992
o-Phenylphenate, sodium	cancer	132-27-4	January 1, 1990
o-Phenylphenol	cancer	90-43-7	August 4, 2000
Phenylphosphine	developmental	638-21-1	August 7, 2009
PhiP(2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine)	male	105650-23-5	October 1, 1994
Pimozide	developmental, female	2062-78-4	August 20, 1999
Pioglitazone	cancer	111025-46-8	April 18, 2014
Pipobroman	developmental	54-91-1	July 1, 1990
Pirimicarb	cancer	23103-98-2	July 1, 2008
Plicamycin	developmental	18378-89-7	April 1, 1990
Polybrominated biphenyls	cancer	---	January 1, 1988
Polybrominated biphenyls	developmental	---	October 1, 1994
Polychlorinated biphenyls	cancer	---	October 1, 1989
Polychlorinated biphenyls	developmental	---	January 1, 1991
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	cancer	---	January 1, 1988
Polychlorinated dibenzo- <i>p</i> -dioxins	cancer	---	October 1, 1992
Polychlorinated dibenzofurans	cancer	---	October 1, 1992
Polygeenan	cancer	53973-98-1	January 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Ponceau MX	cancer	3761-53-3	April 1, 1988
Ponceau 3R	cancer	3564-09-8	April 1, 1988
Potassium bromate	cancer	7758-01-2	January 1, 1990
Potassium dimethyldithiocarbamate	developmental	128-03-0	March 30 1999
Pravastatin sodium	developmental	81131-70-6	March 3, 2000
Prednisolone sodium phosphate	developmental	125-02-0	August 20, 1999
Primidone	cancer	125-33-7	August 20, 1999
Procarbazine	cancer	671-16-9	January 1, 1988
Procarbazine hydrochloride	cancer	366-70-1	January 1, 1988
Procarbazine hydrochloride	developmental	366-70-1	July 1, 1990
Procymidone	cancer	32809-16-8	October 1, 1994
Progesterone	cancer	57-83-0	January 1, 1988
Pronamide	cancer	23950-58-5	May 1, 1996
Propachlor	cancer	1918-16-7	February 27, 2001
1,3-Propane sultone	cancer	1120-71-4	January 1, 1988
Propargite	cancer	2312-35-8	October 1, 1994
Propargite	developmental	2312-35-8	June 15, 1999
Propazine	developmental, female	139-40-2	July 15, 2016
beta-Propiolactone	cancer	57-57-8	January 1, 1988
Propoxur	cancer	114-26-1	August 11, 2006
Propylene glycol mono- <i>t</i> -butyl ether	cancer	57018-52-7	June 11, 2004
Propylene oxide	cancer	75-56-9	October 1, 1988
Propylthiouracil	cancer	51-52-5	January 1, 1988
Propylthiouracil	developmental	51-52-5	July 1, 1990
Pulegone	cancer	89-82-7	April 18, 2014
Pymetrozine	cancer	123312-89-0	March 22, 2011
Pyridine	cancer	110-86-1	May 17, 2002
Pyrimethamine	developmental	58-14-0	January 29, 1999
Quazepam	developmental	36735-22-5	August 26, 1997
Quinoline and its strong acid salts	cancer	---	October 24, 1997
Quizalofop-ethyl	male	76578-14-8	December 24, 1999
Radionuclides	cancer	---	July 1, 1989
Reserpine	cancer	50-55-5	October 1, 1989
Residual (heavy) fuel oils	cancer	---	October 1, 1990
Resmethrin	cancer	10453-86-8	July 1, 2008
Resmethrin	developmental	10453-86-8	November 6, 1998
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)	developmental	---	July 1, 1989
Ribavirin	developmental	36791-04-5	April 1, 1990
Ribavirin	male	36791-04-5	February 27, 2001
Riddelliine	cancer	23246-96-0	December 3, 2004
Rifampin	developmental, female	13292-46-1	February 27, 2001
<a href="#">Saccharin, Delisted April 6, 2001</a>	cancer	<a href="#">81-07-2</a>	<a href="#">October 1, 1989</a>
<a href="#">Saccharin, sodium, Delisted January 17, 2003</a>	cancer	<a href="#">128-44-9</a>	<a href="#">January 1, 1988</a>
Safrole	cancer	94-59-7	January 1, 1988



<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Salted fish, Chinese-style	cancer	---	April 29, 2011
Secobarbital sodium	developmental	309-43-3	October 1, 1992
Sedaxane	cancer	874967-67-6	July 1, 2016
Selenium sulfide	cancer	7446-34-6	October 1, 1989
Sermorelin acetate	developmental	---	August 20, 1999
Shale-oils	cancer	68308-34-9	April 1, 1990
Silica, crystalline (airborne particles of respirable size)	cancer	---	October 1, 1988
Simazine	developmental, female	122-34-9	July 15, 2016
Sodium dimethyldithiocarbamate	developmental	128-04-1	March 30 1999
Sodium fluoroacetate	male	62-74-8	November 6, 1998
Soots, tars, and mineral oils(untreated and mildly treated oils and used engine oils)	cancer	---	February 27, 1987
Spirodiclofen	cancer	148477-71-8	October 8, 2010
Spironolactone	cancer	52-01-7	May 1, 1997
Stanozolol	cancer	10418-03-8	May 1, 1997
Sterigmatocystin	cancer	10048-13-2	April 1, 1988
Streptomycin sulfate	developmental	3810-74-0	January 1, 1991
Streptozocin (streptozotocin)	developmental, female, male	18883-66-4	August 20, 1999
Streptozotocin (streptozocin)	cancer	18883-66-4	January 1, 1988
Strong inorganic acid mists containing sulfuric acid	cancer	---	March 14, 2003
Styrene	cancer	100-42-5	April 22, 2016
Styrene oxide	cancer	96-09-3	October 1, 1988
Sulfallate	cancer	95-06-7	January 1, 1988
Sulfasalazine (Salicylazosulfapyridine)	cancer	599-79-1	May 15, 1998
Sulfasalazine (Salicylazosulfapyridine)	male	599-79-1	January 29, 1999
Sulfur dioxide	developmental	7446-09-5	July 29, 2011
Sulindac	developmental, female	38194-50-2	January 29, 1999
Talc containing asbestiform fibers	cancer	---	April 1, 1990
Tamoxifen and its salts	cancer	10540-29-1	September 1, 1996
Tamoxifen citrate	developmental	54965-24-1	July 1, 1990
Temazepam	developmental	846-50-4	April 1, 1990
Teniposide	developmental	29767-20-2	September 1, 1996
Terbacil	developmental	5902-51-2	May 18, 1999
Teriparatide	cancer	52232-67-4	August 14, 2015
Terrazole	cancer	2593-15-9	October 1, 1994
Testosterone and its esters	cancer	58-22-0	April 1, 1988
Testosterone cypionate	developmental	58-20-8	October 1, 1991
Testosterone enanthate	developmental	315-37-7	April 1, 1990
Tetrabromobisphenol A	cancer	79-94-7	October 27, 2017
3,3',4,4'-Tetrachloroazobenzene	cancer	14047-09-7	July 24, 2012
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	cancer	1746-01-6	January 1, 1988
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	developmental	1746-01-6	April 1, 1991
1,1,1,2-Tetrachloroethane	cancer	630-20-6	September 13, 2013
1,1,2,2-Tetrachloroethane	cancer	79-34-5	July 1, 1990
Tetrachloroethylene (Perchloroethylene)	cancer	127-18-4	April 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
p-a,a,a-Tetrachlorotoluene	cancer	5216-25-1	January 1, 1990
Tetrachlorvinphos	cancer	22248-79-9	May 20, 2016
Tetracycline (internal use)	developmental	60-54-8	October 1, 1991
Tetracyclines (internal use)	developmental	---	October 1, 1992
Tetracycline hydrochloride (internal use)	developmental	64-75-5	January 1, 1991
Tetrafluoroethylene	cancer	116-14-3	May 1, 1997
$\Delta^9$ -Tetrahydrocannabinol ( $\Delta^9$ -THC; delta-9-THC)	developmental		January 3, 2020
Tetrahydrofuran	cancer	109-99-9	December 17, 2021
Tetranitromethane	cancer	509-14-8	July 1, 1990
Thalidomide	developmental	50-35-1	July 1, 1987
Thioacetamide	cancer	62-55-5	January 1, 1988
4,4'-Thiodianiline	cancer	139-65-1	April 1, 1988
Thiodicarb	cancer	59669-26-0	August 20, 1999
Thioguanine	developmental	154-42-7	July 1, 1990
Thiophanate methyl	female, male	23564-05-8	May 18, 1999
Thiouracil	cancer	141-90-2	June 11, 2004
Thiourea	cancer	62-56-6	January 1, 1988
Thorium dioxide	cancer	1314-20-1	February 27, 1987
Titanium dioxide (airborne, unbound particles of respirable size)	cancer	---	September 2, 2011
Tobacco, oral use of smokeless products	cancer	---	April 1, 1988
Tobacco smoke	cancer	---	April 1, 1988
Tobacco smoke (primary)	developmental, female, male	---	April 1, 1988
Tobramycin sulfate	developmental	49842-07-1	July 1, 1990
Toluene	developmental	108-88-3	January 1, 1991
Toluene diisocyanate	female	<del>108-88-3</del>	<del>August 7, 2009</del>
o-Toluidine	cancer	26471-62-5	October 1, 1989
o-Toluidine hydrochloride	cancer	95-53-4	January 1, 1988
<del>para-Toluidine, Delisted October 29, 1999</del>	<del>cancer</del>	<del>636-21-5</del>	<del>January 1, 1988</del>
Topiramate	developmental	97240-79-4	November 27, 2015
Toxaphene (Polychlorinated camphenes)	cancer	8001-35-2	January 1, 1988
Toxins derived from <i>Fusarium</i> Moniliforme ( <i>Fusarium verticillioides</i> )	cancer	---	August 7, 2009
Treosulfan	cancer	299-75-2	February 27, 1987
Triadimefon	developmental, female, male	43121-43-3	March 30, 1999
Triamterene	cancer	396-01-0	April 18, 2014
Triazolam	developmental	28911-01-5	April 1, 1990
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF)	cancer	78-48-8	February 25, 2011
Tributyltin methacrylate	developmental	2155-70-6	December 1, 1999
Trichlormethine (Trimustine hydrochloride)	cancer	817-09-4	January 1, 1992
Trichloroacetic acid	cancer	76-03-9	September 13, 2013
1,1,1-Trichloroethane	cancer	71-55-6	April 21, 2023
Trichloroethylene	cancer	79-01-6	April 1, 1988
Trichloroethylene	developmental, male	79-01-6	January 31, 2014
2,4,6-Trichlorophenol	cancer	88-06-2	January 1, 1988

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
1,2,3-Trichloropropane	cancer	96-18-4	October 1, 1992
Trientine hydrochloride	developmental	38260-01-4	February 27, 2001
Triforine	developmental	26644-46-2	June 18, 1999
<a href="#">1,3,5-Triglycidyl-s-triazinetrione, Delisted December 13, 2013</a>	<a href="#">male</a>	<a href="#">2451-62-9</a>	<a href="#">August 7, 2009</a>
Trilostane	developmental	13647-35-3	April 1, 1990
Trimethadione	developmental	127-48-0	January 1, 1991
2,4,5-Trimethylaniline and its strong acid salts	cancer	---	October 24, 1997
Trimethylolpropane triacrylate, technical grade	cancer	---	December 17, 2021
Trimethyl phosphate	cancer	512-56-1	May 1, 1996
Trimetrexate glucuronate	developmental	82952-64-5	August 26, 1997
TRIM® VX	cancer	---	May 25, 2018
2,4,6-Trinitrotoluene (TNT)	cancer	118-96-7	December 19, 2008
Triphenyltin hydroxide	cancer	76-87-9	July 1, 1992
Triphenyltin hydroxide	developmental	76-87-9	March 18, 2002
<a href="#">Tris(aziridinyl)-p-benzoquinone (Triaziquone), Delisted December 8, 2006</a>	<a href="#">cancer</a>	<a href="#">68-76-8</a>	<a href="#">October 1, 1989</a>
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	cancer	52-24-4	January 1, 1988
Tris(2-chloroethyl) phosphate	cancer	115-96-8	April 1, 1992
Tris(2,3-dibromopropyl)phosphate	cancer	126-72-7	January 1, 1988
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	cancer	13674-87-8	October 28, 2011
Trp-P-1 (Tryptophan-P-1)	cancer	62450-06-0	April 1, 1988
Trp-P-2 (Tryptophan-P-2)	cancer	62450-07-1	April 1, 1988
Trypan blue (commercial grade)	cancer	72-57-1	October 1, 1989
Unleaded gasoline (wholly vaporized)	cancer	---	April 1, 1988
Uracil mustard	cancer	66-75-1	April 1, 1988
Uracil mustard	developmental, female, male	66-75-1	January 1, 1992
Urethane (Ethyl carbamate)	cancer	51-79-6	January 1, 1988
Urethane (Ethyl carbamate)	developmental	51-79-6	October 1, 1994
Urofollitropin	developmental	97048-13-0	April 1, 1990
Valproate (Valproic acid)	developmental	99-66-1	July 1, 1987
Vanadium pentoxide (orthorhombic crystalline form)	cancer	1314-62-1	February 11, 2005
Vinblastine sulfate	developmental	143-67-9	July 1, 1990
Vinclozolin	cancer	50471-44-8	August 20, 1999
Vinclozolin	developmental	50471-44-8	May 15, 1998
Vincristine sulfate	developmental	2068-78-2	July 1, 1990
Vinyl bromide	cancer	593-60-2	October 1, 1988
Vinyl chloride	cancer	75-01-4	February 27, 1987
4-Vinylcyclohexene	cancer	100-40-3	May 1, 1996
4-Vinyl-cyclohexene	female, <a href="#">male</a>	100-40-3	August 7, 2009
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexene dioxide)	cancer	106-87-6	July 1, 1990
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide)	female, <a href="#">male</a>	106-87-6	August 1, 2008
Vinyl fluoride	cancer	75-02-5	May 1, 1997

<u>Chemical</u>	<u>Type of Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Vinylidene chloride (1,1-Dichloroethylene)	cancer	75-35-4	December 29, 2017
Vinyl trichloride (1,1,2-Trichloroethane)	cancer	79-00-5	October 1, 1990
Vismodegib	developmental, female, male	879085-55-9	January 27, 2017
Warfarin	developmental	81-81-2	July 1, 1987
Wood dust	cancer	---	December 18, 2009
2,6-Xylidine (2,6-Dimethylaniline)	cancer	87-62-7	January 1, 1991
Zalcitabine	cancer	7481-89-2	August 7, 2009
Zidovudine (AZT)	cancer	30516-87-1	December 18, 2009
Zileuton	cancer, developmental, female	111406-87-2	December 22, 2000
<a href="#"><u>Zineb, Delisted October 29, 1999</u></a>	<del>cancer</del>	<del>12122-67-7</del>	<del>January 1, 1990</del>
Date: <a href="#"><u>April 21, 2023</u></a>			